UBIQUITIN VARIANT MODULATORS OF HECT E3 LIGASES AND THEIR USES
The invention provides ubiquitin variants that specifically bind to HECT E3 ligases, and methods of using these variants to modulate the activity of HECT E3 ligases.
This invention relates to ubiquitin variants that specifically bind to HECT E3 ligases, and use of these variants to modulate the activity of HECT E3 ligases.
BACKGROUND OF THE INVENTIONUbiquitination mediated by E1-E2-E3 multi-enzyme cascades rivals phosphorylation as a predominant mechanism regulating myriad protein functions (Cohen and Tcherpakov, 2010; Nalepa et al., 2006). Repeated catalytic cycles result in substrates modified on multiple lysines with various polyubiquitin chains, which alter protein functions in an extraordinary variety of ways. Because E3 ligases control substrate specificity and the topology of ubiquitination, they represent attractive targets for therapeutic intervention (Nalepa et al., 2006; Petroski, 2008). Yet, identifying the diversity of mechanisms regulating E3 ligases, as well as generation of tools for their manipulation, has lagged behind deciphering regulation and developing therapeutics for kinases (Cohen and Tcherpakov, 2010; Nalepa et al., 2006). The first family of E3 ligases discovered (Huibregtse et al., 1995), HECT (Homologous to E6AP C-Terminus) E3s, have been directly implicated in cancer, hypertension, neurological disorders, and other diseases (see Table 2, below) (Rotin and Kumar, 2009; Scheffner and Kumar, 2014). Moreover, some pathogenic bacteria have evolved HECT-like E3s as virulence factors to manipulate host cell signaling (Lin et al., 2012; Rohde et al., 2007). Therefore, understanding molecular mechanisms of HECT E3 function could greatly advance therapeutic strategies for many diseases.
Development of agents to selectively modulate HECT E3s has been hampered by extreme inter-domain rotations accompanying catalysis, a shallow active site, and dynamic regulation of HECT E3 activity (Escobedo et al., 2014; Gallagher et al., 2006; Huang et al., 1999; Kamadurai et al., 2013; Kamadurai et al., 2009; Mari et al., 2014; Persaud et al., 2014; Ronchi et al., 2013; Verdecia et al., 2003; Wiesner et al., 2007). In principle, recently reported small molecule and peptide inhibitors obtained by high throughput screening for several HECT E3s provide routes to assess functions and mechanisms of HECT E3s in normal and diseased cells (Cao et al., 2014; Kathman et al., 2015; Mund et al., 2014; Rossi et al., 2014). However, existing molecules generally do not conform to a general strategy that could be used to interrogate HECT E3s across the family, fall short in terms of potency and specificity, and generally have had limited utility in probing unknown HECT mechanisms.
The defining feature of HECT E3s is a ˜40 kDa C-terminal “HECT domain” containing two flexibly-tethered lobes (N- and C-), with 16-92% amino acid identity across the family. In addition to the catalytic domain, HECT E3 primary sequences reveal various N-terminal domains that may enable substrate binding and dynamic regulation by mediating autoinhibition and influencing subcellular localization (FIG. 1A). The largest and best-characterized class of HECT E3s comprises the NEDD4-family, which display a common architecture consisting of an N-terminal C2 domain, 2-4 central WW-domains distal and proximal to the catalytic domain, and the C-terminal HECT domain (Rotin and Kumar, 2009; Scheffner and Kumar, 2014) (
Studies of E3s in the NEDD4-family revealed that the HECT domain interacts with Ub at multiple sites. For example, in complex with E2˜Ub or in the E3˜Ub intermediate, the HECT “C-lobe” binds the Ub to be transferred, and a separate C-lobe interaction with the acceptor Ub is implied from biochemical studies (Kamadurai et al., 2013; Kamadurai et al., 2009; Kim and Huibregtse, 2009; Maspero et al., 2013). In addition to interactions made by the active-site-bound Ub, a weak Ub-binding “exosite” has been reported in the HECT “N-lobe” of various NEDD4-family E3s (French et al., 2009; Kim et al., 2011; Maspero et al., 2011; Ogunjimi et al., 2010).
SUMMARY OF THE INVENTIONIn a first aspect, the invention provides ubiquitin variant (Ubv) polypeptides that include one or more substitution in one or more region of a ubiquitin polypeptide, wherein the region is selected from the group consisting of:
(a) region 1 (amino acids 2-14 of SEQ ID NO:1) wherein the polypeptide comprises the structure:
X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14
wherein
X2 is selected from the group consisting of A, D, E, H, K, L, P, Q, R, S, T, and Y;
X4 is selected from the group consisting of A, C, F, I, L, R, S, V, and Y;
X6 is selected from the group consisting of E, G, H, I, K, N, Q, R, S, V, W, and Y;
X8 is selected from the group consisting of F, G, H, I, L, M, P, R, V, and Y;
X9 is selected from the group consisting of A, F, G, I, K, L, M, N, P, R, S, and T;
X10 is selected from the group consisting of A, D, G, L, R, V, and W;
X11 is selected from the group consisting of D, E, H, I, K, L, M, N, P, Q, R, T, V, W, and Y;
X12 is selected from the group consisting of D, G, I, L, N, P, S, T, V, and Y;
X14 is selected from the group consisting of A, C, F, I, K, N, P, R, S, and T; and
any X not specified optionally has the amino acid sequence of the corresponding position in SEQ ID NO:1;
(b) region 2 (amino acids 42-49 of SEQ ID NO:1) wherein the polypeptide comprises the structure:
X42-X43-X44-X-45-X46-X47-X48-X49 wherein
X42 is selected from the group consisting of F, G, I, K, L, Q, R, S, T, and V;
X44 is selected from the group consisting of F, I, L, T, and V;
X46 is selected from the group consisting of A, G, H, L, R, S, T, and V;
X47 is selected from the group consisting of A, D, G, R, S, and W;
X48 is selected from the group consisting of K, M, N, Q, R, and T;
X49 is selected from the group consisting of D, E, H, I, K, N, P, Q, R, and S; and
any X not specified optionally has the amino acid sequence of the corresponding position in SEQ ID NO:1; and
(c) region 3 (amino acids 62-78 of SEQ ID NO:1) wherein the polypeptide comprises the structure:
X62-X63-X64-X65-X66-X67-X68-X69-X70-X71-X72-X73-X74-X75-X76-X77-X78
wherein
X62 is selected from the group consisting of C, H, K, L, P, Q, R, and Y;
X63 is selected from the group consisting of D, E, G, H, K, M, N, Q, R, and Y;
X64 is selected from the group consisting of A, D, E, F, G, K, Q, R, T, V, W, and Y;
X66 is selected from the group consisting of A, F, H, I, L, N, P, Q, R, S, T, and W;
X68 is selected from the group consisting of G, F, H, L, N, R, S, T, W, and Y;
X70 is selected from the group consisting of A, I, F, K, L, M, R, V, and W;
X71 is selected from the group consisting of F, G, K, L, M, R, V, and Y;
X72 is selected from the group consisting of G, I, K, P, Q, R, S, and T;
X73 is selected from the group consisting of F, I, L, P, R, and T;
X74 is selected from the group consisting of L, H, I, P, R, and V;
X75 is selected from the group consisting of A, D, G, I, P, R, V, W, and Y;
X76 is selected from the group consisting of A, D, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, and Y;
X77 is selected from the group consisting of A, D, E, F, H, I, K, M, N, P, Q, R, S, T, V, and Y, or is absent;
X78 is selected from the group consisting of A, D, E, F, H, I, K, L, N, P, Q, R, S, T, V, W, and Y, or is absent; and any X not specified optionally has the amino acid sequence of the corresponding position in SEQ ID NO:1;
wherein any X specified in said Ubv polypeptide optionally has the amino acid sequence of the corresponding position in SEQ ID NO:1; or a fragment thereof, wherein the sequence of said Ubv polypeptide does not consist of SEQ ID NO:1.
As noted above, any X not specified can optionally have the amino acid sequence of the corresponding position in SEQ ID NO:1 or, alternatively, the sequence of the corresponding position in any of the specific Ubv's listed herein, if different from that of SEQ ID NO:1.
In a first embodiment, the Ubv polypeptide binds to NEDD4 (N4). In this embodiment, the sequence of the Ubv polypeptide can include, for example, a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:2-4 or a fragment thereof. In specific examples, the sequence of the Ubv polypeptide includes a sequence selected from the group consisting of SEQ ID NOs:2-4.
In a second embodiment, the Ubv polypeptide binds to NEDD4L (NL). In this embodiment, the sequence of the Ubv polypeptide can include, for example, a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:5-8. In specific examples, the sequence of the Ubv polypeptide includes a sequence selected from the group consisting of SEQ ID NOs:5-8.
In a third embodiment, the Ubv polypeptide binds to ITCH (IT). In this embodiment, the sequence of the Ubv polypeptide can include, for example, a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:9-12. In specific examples, the sequence of the Ubv polypeptide includes a sequence selected from the group consisting of SEQ ID NOs:9-12.
In a fourth embodiment, the Ubv polypeptide binds to SMURF1 (S1). In this embodiment, the sequence of the Ubv polypeptide can include, for example, a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:13-17. In specific examples, the sequence of the Ubv polypeptide includes a sequence selected from the group consisting of SEQ ID NOs:13-17.
In a fifth embodiment, the Ubv polypeptide binds to SMURF2 (S2). In this embodiment, the sequence of the Ubv polypeptide can include, for example, a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:18-22. In specific examples, the sequence of the Ubv polypeptide includes a sequence selected from the group consisting of SEQ ID NOs:18-22.
In a sixth embodiment, the Ubv polypeptide binds to WWP1 (P1). In this embodiment, the sequence of the Ubv polypeptide can include, for example, a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:23-26. In specific examples, the sequence of the Ubv polypeptide includes a sequence selected from the group consisting of SEQ ID NOs:23-26.
In a seventh embodiment, the Ubv polypeptide binds to WWP2 (P2). In this embodiment, the sequence of the Ubv polypeptide can include, for example, a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:27-30. In specific examples, the sequence of the Ubv polypeptide includes a sequence selected from the group consisting of SEQ ID NOs:27-30.
In an eighth embodiment, the Ubv polypeptide binds to HECW1 (W1). In this embodiment, the sequence of the Ubv polypeptide can include, for example, a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:31-34. In specific examples, the sequence of the Ubv polypeptide includes a sequence selected from the group consisting of SEQ ID NOs:31-34.
In a ninth embodiment, the Ubv polypeptide binds to HECW2 (W2). In this embodiment, the Ubv polypeptide can include, for example, a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:35-38. In specific examples, the sequence of the Ubv polypeptide includes a sequence selected from the group consisting of SEQ ID NOs:35-38.
In a tenth embodiment, the Ubv polypeptide binds to RSP5 (R5). In this embodiment, the sequence of the Ubv polypeptide can include, for example, a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:39-44. In specific examples, the Ubv polypeptide includes a sequence selected from the group consisting of SEQ ID NOs:39-44.
In an eleventh embodiment, the Ubv polypeptide binds to HERC1 (H1). In this embodiment, the sequence of the Ubv polypeptide can include, for example, a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:45 and 46. In specific examples, the sequence of the Ubv polypeptide includes a sequence selected from the group consisting of SEQ ID NOs:45 and 46.
In a twelfth embodiment, the Ubv polypeptide binds to HERC2 (H2). In this embodiment, the Ubv polypeptide can include, for example, a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:47 and 48. In specific examples, the sequence of the Ubv polypeptide includes a sequence selected from the group consisting of SEQ ID NOs:47 and 48.
In a thirteenth embodiment, the Ubv polypeptide binds to HERC4 (H4). In this embodiment, the Ubv polypeptide can include, for example, a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:49-52. In specific examples, the sequence of the Ubv polypeptide includes a sequence selected from the group consisting of SEQ ID NOs:49-52.
In a fourteenth embodiment, the Ubv polypeptide binds to HERC6 (H6). In this embodiment, the sequence of the Ubv polypeptide can include, for example, a sequence that is at least 90% identical to SEQ ID NO:53. In a specific example, the sequence of the Ubv polypeptide includes SEQ ID NO:53.
In a fifteenth embodiment, the Ubv polypeptide binds to HACE1 (HA). In this embodiment, the sequence of the Ubv polypeptide can include, for example, a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:54-56. In specific examples, the sequence of the Ubv polypeptide includes a sequence selected from the group consisting of SEQ ID NOs:54-56.
In a sixteenth embodiment, the Ubv polypeptide binds to HUWE1 (HU). In this embodiment, the sequence of the Ubv polypeptide can include, for example, a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:57 and 58. In specific examples, the Ubv polypeptide includes a sequence selected from the group consisting of SEQ ID NOs:57 and 58.
In a seventeenth embodiment, the Ubv polypeptide binds to UBE3C (3C). In this embodiment, the sequence of the Ubv polypeptide can include, for example, a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:59 and 60. In specific examples, the sequence of the Ubv polypeptide includes a sequence selected from the group consisting of SEQ ID NOs:59 and 60.
In an eighteenth embodiment, the Ubv polypeptide binds to HECTD1 (D1). In this embodiment, the sequence of the Ubv polypeptide can include, for example, a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:61-64. In specific examples, the sequence of the Ubv polypeptide includes a sequence selected from the group consisting of SEQ ID NOs:61-64.
In a nineteenth embodiment, the Ubv polypeptide binds to EDD1 (ED). In this embodiment, the sequence of the Ubv polypeptide can include, for example, a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:65 and 66. In specific examples, the sequence of the Ubv polypeptide includes a sequence selected from the group consisting of SEQ ID NOs:65 and 66.
In a twentieth embodiment, the Ubv polypeptide binds to KIAA0317 (KI). In this embodiment, the sequence of the Ubv polypeptide can include, for example, a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:67-70. In specific examples, the sequence of the Ubv polypeptide is selected from the group consisting of SEQ ID NOs:67-70.
In further embodiments, the Ubv polypeptide includes a fragment of a polypeptide having a sequence identifier noted above or a sequence at least 90% identical thereto.
In another aspect, the invention includes nucleic acid molecules that encode Ubv polypeptides or fragments thereof as described herein. In related aspects, the invention includes recombinant expression vectors that include such nucleic acid molecules, as well as host cells that include such nucleic acid molecules and/or vectors.
In a further aspect, the invention provides methods of obtaining a Ubv polypeptide that modulates an activity or property of a HECT E3 ligase. These methods can include, for example, steps of: (a) randomizing ubiquitin residues to produce a combinatorial library of Ubv polypeptides, and (b) selecting Ubv polypeptides that specifically bind to one or more HECT E3 ligase. In various embodiments, the randomized residues (a) contact the N-lobe exosite of a HECT E3 ligase, (b) contact the E2 site of a HECT E3 ligase, and/or (c) are within region 1 (amino acids 2-14), region 2 (amino acids 42-49), and/or region 3 (amino acids 62-78) of ubiquitin. Furthermore, in various examples, the HECT E3 ligase is selected from the group consisting of NEDD4 (N4), NEDD4L (NL), ITCH (IT), SMURF1 (S1), SMURF2 (S2), WWP1 (P1), WWP2 (P2), HECW1 (W1), HECW2 (W2), RSP5 (R5), HERC1 (H1), HERC2 (H2), HERC3 (H3), HERC4 (H4), HERC5 (H5), HERC6 (H6), HACE1 (HA), HUWE1 (HU), UBE3A (3A), UBE3B (3B), UBE3C (3C), HECTD1 (D1), EDD1 (ED), KIAA0317 (KI), HECTD1, HECTD2, HECTD3, HECTD4, G2E3, and TRIP12. The methods can optionally include one or more steps in which a selected Ubv is assessed for its effects on an activity of a HECT E3 ligase or on a cellular function or activity modulated by a HECT E3 ligase.
In an additional aspect, the invention includes methods of modulating (e.g., increasing or decreasing) an activity or property of a HECT E3 ligase. These methods can optionally include, for example, contacting the HECT E3 ligase with an agent that binds to the N-lobe exosite of the HECT E3 ligase or to the E2 site of the HECT E3 ligase. In various embodiments, the agent includes a Ubv polypeptide, a nucleic acid molecule encoding a Ubv polypeptide, or a fragment thereof. Optionally, the Ubv polypeptide is a Ubv polypeptide as described herein, or a fragment thereof, or the nucleic acid molecule is a nucleic acid molecule as described herein, or a fragment thereof. The agent may have specificity for a particular HECT E3 ligase, or may be active against more than one HECT E3 ligase. In certain embodiments, the HECT E3 ligase is in a cell, which may optionally be within a subject (e.g., a human subject), who optionally has a disease or condition selected from the group consisting of hypertension, inflammation, and cancer. In a related aspect, the invention provides methods of treating hypertension, inflammation, or cancer in a subject (e.g., a human subject), by modulating (e.g., increasing or decreasing) the activity of a HECT E3 ligase in a cell of the subject according to the methods as described herein.
In a further aspect, the invention includes methods of identifying agents that modulate the activity of a HECT E3 ligase. These methods optionally include contacting a complex including a HECT E3 ligase and a Ubv polypeptide that binds to the HECT E3 ligase with a candidate agent (e.g., a small molecule compound or a peptide), and determining whether the agent affects the binding of the Ubv to the HECT E3 ligase or an activity of the complex. In various embodiments, the HECT E3 ligase is selected from the group consisting of NEDD4 (N4), NEDD4L (NL), ITCH (IT), SMURF1 (S1), SMURF2 (S2), WWP1 (P1), WWP2 (P2), HECW1 (W1), HECW2 (W2), RSP5 (R5), HERC1 (H1), HERC2 (H2), HERC3 (H3), HERC4 (H4), HERC5 (H5), HERC6 (H6), HACE1 (HA), HUWE1 (HU), UBE3A (3A), UBE3B (3B), UBE3C (3C), HECTD1 (D1), EDD1 (ED), KIAA0317 (KI), HECTD1, HECTD2, HECTD3, HECTD4, G2E3, and TRIP12. In further embodiments, the Ubv polypeptide is selected from a Ubv polypeptide as described herein, or a fragment thereof.
Other features and advantages of the invention will be apparent from the following detailed description, the drawings, and the claims.
The attachment of ubiquitin (Ub) to target proteins involves the activities of Ub-activating enzymes (E1 enzymes), Ub-conjugating enzymes (E2 enzymes), and Ub ligases (E3 enzymes). Ubiquitination can alter the properties of target proteins in many ways, including directing them to the proteosome for degradation, as well as altering their cellular localization, activities, and/or interactive properties with respect to other proteins. Modification of ubiquitination thus provides an opportunity to modify a very wide variety of different cellular functions, in many contexts.
The present invention provides ubiquitin (Ub) variants, or UbVs, which target a particular family of E3 ligases, HECT E3 ligases. The invention also provides nucleic acid molecules encoding such UbVs, as well as related vectors and cells. In addition, the invention provides methods for identifying and characterizing new HECT E3 ligase-specific UbVs. Furthermore, the invention provides methods of using UbV polypeptides and related molecules. Examples of the latter include, for example, methods of identifying other modulators of HECT E3 ligase activity, as well as therapeutic methods involving HECT E3 ligase activity modulation. These and other aspects of the invention are described further, as follows.
The UbVs of the invention bind to or otherwise impact the activity of one or more HECT E3 ligase. The UbVs of the invention can have broad activity, against a wide range of HECT E3 ligases or, alternatively, may be relatively specific, modulating the activity of a small, related subset of HECT E3 ligases or even only a single, specific HECT E3 ligase. The UbVs modulate the activity of a HECT E3 ligase by, for example, increasing or decreasing the ligase activity. The modulation (increasing or decreasing of activity) can be by direct interaction with a HECT E3 ligase active site. In one example of such an interaction, a UbV binds to the active site of a HECT E3 ligase with greater affinity than Ub, resulting in competitive inhibition. In another example, the UbV blocks the active site after an enzymatic reaction, resulting in product inhibition. Alternatively, the modulation may be by an allosteric means, in which the UbV, for example, binds outside of the active site and impacts activity. In addition, the UbVs can function by binding different sites on HECT E3 ligases including, for example, the E2 binding site on HECT E3 ligases and/or the N-lobe exosite of HECT E3 ligases.
HECT E3 ligases that can be targeted by the UbVs of the invention include, for example, the following human HECT E3 ligases: NEDD4 (N4), NEDD4L (NL), ITCH (IT), SMURF1 (S1), SMURF2 (S2), WWP1 (P1), WWP2 (P2), HECW1 (W1), HECW2 (W2), HERC1 (H1), HERC2 (H2), HERC3 (H3), HERC4 (H4), HERC5 (H5), HERC6 (H6), HACE1 (HA), HUWE1 (HU), UBE3A (3A), UBE3B (3B), UBE3C (3C), HECTD1 (D1), EDD1 (ED), KIAA0317 (KI), HECTD2, HECTD3, HECTD4, G2E3, and TRIP12. Additional HECT E3 ligases that can be targeted include HECT E3 ligases from budding yeast (e.g., Rsp5 (R5), Hul4, Hul5, Tom1, and Ufd4) and pathogenic bacteria Salmonella (SopA and NIeL).
The UbVs of the invention comprise one or more mutation (e.g., substitution, deletion, addition, or modification) within any region or regions of a wild-type Ub. Using the sequence of human ubiquitin as a reference (SEQ ID NO:1), the UbVs can have mutations (e.g., substitutions or deletions) in one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14) amino acid in one or more of region 1 (amino acids 2-14), region 2 (42-49), or region 3 (62-78). A wild-type variant having two C-terminal glycines added to the sequence of SEQ ID NO:1 can also serve as a basis for generating UbVs. Furthermore, in addition to human Ub, the invention features UbVs obtained on the basis of Ub from other species and sources.
The sequence of Ub and specific examples of UbVs of the invention are provided in Table 1.
In addition to UbVs having the sequences set forth above, the invention includes variants of these and other UbVs. Thus, for example, the invention includes polypeptides having at least 80%, 85%, 95%, or 99% sequence identity to a UbV, such as a UbV described herein. The invention also includes UbV variants having one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) substitutions (e.g., conservative amino acid substitutions) and/or deletions relative to a sequence provided herein. Also see the formula in the Summary of the Invention, above.
A “conservative” amino acid substitution as used herein, is one in which one amino acid residue is replaced with another amino acid residue having similar properties. Conservative substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine, and leucine; aspartic acid, glutamic acid, asparagine, and glutamine; serine and threonine; lysine and arginine; and phenylalanine and tyrosine. In more detail, conserved amino acid substitutions involve replacing one or more amino acids of the polypeptides of the invention with one or more amino acids of similar charge, size, and/or hydrophobicity characteristics. When only conserved substitutions are made, the resulting molecule may be functionally equivalent or similar to the original molecule. Changes that result in production of a chemically equivalent or chemically similar amino acid sequence are included within the scope of the invention. In various examples, a hydrophobic residue, such as glycine, can be substituted for another hydrophobic residue such as alanine. An alanine residue may be substituted with a more hydrophobic residue such as leucine, valine, or isoleucine. A negatively charged amino acid, such as aspartic acid, may be substituted for glutamic acid. A positively charged amino acid such as lysine may be substituted for another positively charged amino acid, such as arginine. The phrase “conservative substitution” also includes the use of a chemically derivatized residue in place of a non-derivatized residue, provided that such polypeptide displays a requisite activity.
The invention includes polypeptides that comprise the sequences of the UbVs described herein, in addition to other sequences. Thus, for example, the invention includes fusion proteins comprising the UbVs (and variants thereof) described herein (e.g., fusions with GST, His, Flag, or Myc tags). In addition, the invention includes fragments of the UbVs (and variants thereof) described herein. Such fragments include, for example, a UbV (or variant thereof) having 1-30 (e.g., 2-25, 4-30, or 5-10) amino acids deleted from either or both ends of the UbV (or variant thereof). Internal deletions are also included in the invention. The fragments can optionally be comprised within a fusion protein, as described above in connection with full-length UbVs. Optionally, UbV variants and fragments maintain, at least in part, one or more activities of the UbV from which they are derived. The fragments can further optionally comprise one or more region of a UbV, as described herein (e.g., region 1, region 2, region 3, region 1 and 2, region 2 and 3, etc.)
The UbVs of the invention can be used to obtain or design peptide mimetics, which are also included in the invention. Peptide mimetics include synthetic structures that may serve as substitutes for peptides in interactions between molecules, and include synthetic structures which can optionally contain amino acids and/or peptide bonds, but are designed to retain the desired structural and functional features and thus may be suitable substitutes of the peptide inhibitor analog disclosed herein. Peptide mimetics also include molecules incorporating peptides into larger molecules with other functional elements (e.g., as described in WO 99/25044). Peptide mimetics also include peptoids, oligopeptoids (Simon et al (1972) Proc. Natl. Acad. Sci. USA 89:9367), and peptide libraries containing peptides of a designed length representing all possible sequences of amino acids corresponding to an isolated peptide of the disclosure. Peptide mimetics may be designed based on information obtained by systematic replacement of L-amino acids by D-amino acids, replacement of side chains with groups having different electronic properties, and by systematic replacement of peptide bonds with amide bond replacements. Local conformational constraints can also be introduced to determine conformational requirements for activity of a candidate peptide mimetic. The mimetics may include isosteric amide bonds, or D-amino acids to stabilize or promote reverse turn conformations and to help stabilize the molecule. Cyclic amino acid analogues may be used to constrain amino acid residues to particular conformational states. The mimetics can also include mimics of inhibitor peptide secondary structures. These structures can model the 3-dimensional orientation of amino acid residues into the known secondary conformations of proteins. Peptoids may also be used which are oligomers of N-substituted amino acids and can be used as motifs for the generation of chemically diverse libraries of novel molecules.
The UbVs described herein can be made using standard methods including, for example, recombinant methods. The UbVs may also be prepared by chemical synthesis using techniques well known in the art such as solid phase synthesis (Merrifield, J. Am. Chem. Assoc. 85:2149-2154 (1964); Frische et al., J. Pept. Sci. 2(4): 212-22 (1996)) or synthesis in homogenous solution (Houbenweyl, Methods of Organic Chemistry, ed. E. Wansch, Vol. 15 I and II, Thieme, Stuttgart (1987)). The UbVs of the invention typically comprise naturally occurring amino acids. However, UbVs including one or more non-naturally occurring amino acid are also included in the invention.
In addition to the UbVs described above, the invention provides nucleic acid molecules encoding the UbVs (e.g., nucleic acid molecules encoding UbVs of any one of SEQ ID NOs:2-70) and variants thereof, as described herein.
The term “nucleic acid molecule” as used herein refers to a sequence of nucleotide or nucleoside monomers consisting of naturally occurring bases, sugars, and intersugar (backbone) linkages. The term also includes modified or substituted sequences comprising non-naturally occurring monomers or portions thereof, which function similarly. The nucleic acid molecules of the present invention can be ribonucleic (RNA) or deoxyribonucleic acids (DNA), and can contain naturally occurring bases including adenine, guanine, cytosine, thymidine, and uracil. The sequences can also contain modified bases such as xanthine, hypoxanthine, 2-aminoadenine, 6-methyl, 2-propyl, and other alkyl adenines, 5-halo uracil, 5-halo cytosine, 6-aza uracil, 6-aza cytosine and 6-aza thymine, pseudo uracil, 4-thiouracil, 8-halo adenine, 8-amino adenine, 8-thiol adenine, 8-thio-alkyl adenines, 8-hydroxyl adenine and other 8-substituted adenines, 8-halo guanines, 8-amino guanine, 8-thiol guanine, 8-thioalkyl guanines, 8-hydroxyl guanine and other 8-substituted guanines, other aza and deaza uracils, thymidines, cytosines, adenines, or guanines, 5-trifluoromethyl uracil, and 5-trifluoro cytosine.
The term “isolated and purified” as used herein refers to a nucleic acid molecule, polypeptide, or peptide that is substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or chemical precursors, or other chemicals when chemically synthesized. An “isolated and purified” nucleic acid molecule is also substantially free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5′ and 3′ ends of the nucleic acid) from which the nucleic acid molecule is derived.
Nucleic acid molecules encoding the UbVs can optionally be comprised within a vector, such as an expression vector. Exemplary vector types include cosmids, plasmids, or modified viruses (e.g. replication defective retroviruses, adenoviruses, and adeno-associated viruses). The expression vectors can include a nucleic acid molecule encoding a UbV, as well as operatively linked regulatory sequences that are selected based on the type of host cells in which expression is to occur. “Operatively linked” is intended to mean that the nucleic acid molecule is linked to regulatory sequences in a manner that allows expression of the nucleic acid under the control of the regulatory element.
The invention thus includes recombinant expression vectors comprising a nucleic acid molecule encoding a UbV, as described herein, and optionally regulatory sequences that direct transcription of the nucleic acid molecule. Suitable regulatory sequences are known in the art and can be obtained from a variety of sources, including bacterial, fungal, viral, mammalian, and insect genes. Selection of appropriate regulatory sequences is dependent on the host cell chosen, and may be readily accomplished by one of ordinary skill in the art. Examples of such regulatory sequences include: a transcriptional promoter and enhancer or RNA polymerase binding sequence, a ribosomal binding sequence, including a translation initiation signal. Additionally, depending on the host cell chosen and the vector employed, other sequences, such as an origin of replication, additional DNA restriction sites, enhancers, and sequences conferring inducibility of transcription may be incorporated into the expression vector. Furthermore, the recombinant expression vectors may also contain a selectable marker gene which facilitates the selection of host cells transformed or transfected with a recombinant molecule of the disclosure. Examples of selectable marker genes are genes encoding a protein such as G418 and hygromycin, which confer resistance to certain drugs, β-galactosidase, chloramphenicol acetyltransferase, firefly luciferase, or an immunoglobulin or portion thereof such as the Fc portion of an immunoglobulin optionally IgG.
Transcription of the selectable marker gene is monitored by changes in the concentration of the selectable marker protein such as β-galactosidase, chloramphenicol acetyltransferase, or firefly luciferase. If the selectable marker gene encodes a protein conferring antibiotic resistance such as neomycin resistance transformant cells can be selected with G418. Cells that have incorporated the selectable marker gene will survive, while the other cells die. This makes it possible to visualize and assay for expression of recombinant expression vectors. It will be appreciated that selectable markers can be introduced on a separate vector from the nucleic acid of interest.
The recombinant expression vectors can also contain genes that encode a fusion moiety which provides increased expression of the recombinant protein; increased solubility of the recombinant protein; and aid in the purification of the target recombinant protein by acting as a ligand in affinity purification. For example, a proteolytic cleavage site may be added to the target recombinant protein to allow separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Typical fusion expression vectors include pGEX (Amrad Corp., Melbourne, Australia), pMal (New England Biolabs, Beverly, Mass.), and pRIT5 (Pharmacia, Piscataway, N.J.), which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the recombinant protein.
Recombinant expression vectors can be introduced into host cells to produce transformed host cells, which are also included in the invention. Suitable host cells include a wide variety of eukaryotic host cells and prokaryotic cells. For example, the UbVs of the invention can be expressed in mammalian, insect, yeast, or bacterial cells (e.g., E. coli).
The nucleic acid molecules of the invention may also be chemically synthesized using standard techniques. Various methods of chemically synthesizing nucleic acid molecules are known, including solid-phase synthesis which, like peptide synthesis, has been fully automated in commercially available DNA synthesizers (see, e.g., Itakura et al., U.S. Pat. No. 4,598,049; Caruthers et al., U.S. Pat. No. 4,458,066; and Itakura, U.S. Pat. Nos. 4,401,796 and 4,373,071).
As noted above, the invention provides methods of identifying and characterized HECT E3 ligase-specific UbVs. Such UbVs can be obtained by screening libraries of Ub variants, which can be generated by randomizing the entire sequence of ubquitin (SEQ ID NO:1) or particular regions (e.g., one or more of regions 1 (2-14), 2 (42-49), and 3 (62-78), or portions thereof). Randomization can be achieved using standard methods of genetic engineering. For example, variants can be created in which a particular residue is replaced with a different amino acid, such that a library of variants comprising all 20 amino acids in each position (e.g., within one or more of regions 1, 2, and 3) is produced. In one example, randomization is performed to yield 75% wild type amino acid residues and 25% mutated amino acid residues within, e.g., one or more of regions 1, 2, and 3.
UbV libraries (e.g., phage display libraries) can be screened against one or more HECT E3 ligase (e.g., see the list set forth above) and/or a fragment of one or more HECT E3 ligase. In one example, the libraries are screened against the HECT domain of one or more HECT E3 ligase (see, e.g.,
UbVs identified as binding to a HECT E3 ligase (or fragment thereof) can then be subject to further characterization including, for example, assessment of binding affinity by EC50 determination, specificity for particular HECT E3 ligases (or subgroups thereof), structural features (e.g., by co-crystallization analysis), and effects on ubiquitination. The latter effects of UbVs can be assessed using in vitro ubiquitination assays, as well as in cell-based assays that assess the effects of a UbV on downstream effects of ubiquitination involving a particular HECT E3 ligase. Details of exemplary assays that can be used in this aspect of the invention are provided in the Examples, below.
In addition to being identified and characterized in various assays, as described above, UbVs identified in the screening of libraries can be subject to further mutagenesis, in order to identify additional UbVs having desirable features. Thus, for example, UbVs found to have a desirable property (e.g., binding specificity), but lacking another features (e.g., binding affinity) can be further mutagenized and re-screened, optionally with the sequences of residues surmised by sequence analysis to be important with respect to the already obtained desirable property (e.g., binding specificity) maintained.
The invention also provides methods for modulating HECT E3 ligase activity. These methods include in vivo modulation of HECT E3 ligase activity by administration of a UbV as described herein, or a nucleic acid molecule encoding such a UbV (e.g., a nucleic acid molecule in an expression or delivery vector, such as a vector as described herein) to a subject (e.g., a human patient). Ex vivo methods, in which a UbV polypeptide or nucleic acid molecule is contacted with a cell or tissue that is then introduced into a subject for therapeutic purposes, are also included in the invention.
The therapeutic methods of the invention can be used in the prevention or treatment of diseases and conditions in which HECT E3 ligases have been implicated including, for example, cancer, hypertension, autoimmune diseases, and neurological disorders. Examples of cancer types that can be treated according to the methods of the invention include ovarian cancer, leukemia, lung cancer, colon cancer, CNS cancer, melanoma, renal cancer, prostate cancer, pancreatic cancer, and breast cancer. Specific examples of non-cancer diseases that can be treated according to the invention include Liddle's syndrome, Angelman disease, Angelman-like disease, Huntington disease, and Kaufman oculocerebrofacial syndrome. In addition, UbVs may be used therapeutically in the context of, for example, wound healing, transplantation, and organ culture, in view of the present observations relating to impact on cell migration. Furthermore, as HECT-like E3 ligases have been identified as virulence factors in certain pathogenic bacteria, UbV treatment can be used in the prevention and treatment of microbial infection.
The invention also includes methods of identifying additional agents that can be used to modulate HECT E3 ligase activity, and thus which can be used in the therapeutic methods described above. In such methods, a complex comprising a UbV and a HECT E3 ligase (or a fragment thereof, such as a HECT domain) is contacted with a candidate agent to determine whether the candidate agent impacts the ability of the UbV to bind to the HECT E3 ligase (or fragment thereof). An agent that affects the binding (e.g., decreases or increases the binding) can be considered as a candidate for modulation of HECT E3 ligase activity and, thus, may be considered for use in a therapeutic method (e.g., see above). Such candidate agents can be tested in an in vitro ubiquitination assay or in cell-based assays, such as those described herein. Candidate agents that can be screened in such assays include, e.g., peptides, nucleic acid molecules, natural products, and small organic or inorganic molecules. Such agents may be present in the context of a library, which can be tested in a high throughput manner.
The following non-limiting examples are illustrative of the present disclosure:
Experimental Examples Development of Potent and Selective UbV Modulators for 20 HECT E3 LigasesWe used a phage-displayed UbV library that varies almost all residues contacting the N-lobe exosite but only a subset of those mediating interactions in the transient catalytic intermediates. Binding selections (
Whereas previous studies confirmed that DUB catalytic activity is potently inhibited by associated UbVs targeting their substrate-binding sites (Ernst et al., 2013; Phillips et al., 2013; Zhang et al., 2013), we hypothesized that UbVs targeting different sites on HECT E3s may modulate ligase activity in a variety of ways that might not involve the active site. To explore how UbVs could influence intrinsic HECT ligase enzyme activity, we monitored E3 autoubiquitination and observed a wide range of effects for 65 UbVs assayed with 20 HECT E3s (
To gain insights into the basis for specific interactions and the mechanisms whereby UbVs inhibit, activate or modulate activity, we attempted co-crystallization of numerous HECT domain-UbV complexes, with or without E2s. We focused on members of the NEDD4-family because they regulate crucial physiological processes ranging from blood pressure to immunity, their catalytic mechanisms are better characterized than those of other HECT E3s (Scheffner and Kumar, 2014), and their UbVs displayed a perplexing variety of effects despite the perceived common catalytic mechanism across this subfamily (
Unexpectedly, UbV P1.1 on WWP1 and UbV IT.2 on ITCH inhibit not by binding a known Ub-binding site, but rather, by occupying the E2-binding site (Huang et al., 1999), which appears to be partially mobile based on the variety of conformations observed in previous structures of WWP1, ITCH, and other HECT domains (
The other four structures showed UbVs binding the N-lobe exosite of NEDD4, NEDD4L, WWP1 or Rsp5 in a manner resembling the previously described binding of Ub at this site (Kim et al., 2011; Maspero et al., 2011) (
We therefore tested whether the NEDD4-family N-lobe exosite generally recruits an acceptor Ub and/or relieves allosteric autoinhibition mediated by the C2 domain. For NEDD4L and WWP1, we used pulse-chase assays that produce free Ub˜Ub chains to monitor Ub transfer from the E3 to an acceptor Ub. Because rapid HECT E3 autoubiquitination precludes generation of stable HECT˜Ub intermediates, we initiated the reactions with thioester-bonded E2˜Ub intermediates for the E2 UBCH7 using a fluorescently-labeled version of Ub. Adding the E2˜Ub to an active HECT E3 along with or without excess free Ub and substrate tests the effects of UbVs on E3-mediated Ub transfer from E2 to E3 to substrate or acceptor Ub. The reactions generate a thioester-bonded E3˜Ub, isopeptide-linked Ub˜Ub or ubiquitinated substrate product readily detected by SDS-PAGE (
To further probe how UbVs differentially modulate HECT E3 activities, we performed a battery of experiments with various substrates using either WT Ub or methylated Ub that cannot form chains (
Interestingly, the effect of UbV binding to the N-lobe exosite on WWP1 differs from the effect on NEDD4L (
Given the utility of the UbVs for probing HECT E3 functions in vitro, and the parallel effects of UbV NL.1 on increasing Ub chain formation in mammalian cells (
We also evaluated the effects of UbVs targeting NEDD4L on regulation of its best-characterized substrate, the Epithelial Na+ Channel, ENaC (SCNN1) (Kamynina et al., 2001; Kimura et al., 2011). Kidney-derived epithelial MDCK cells stably expressing αβγENaC and activator NL.1 or inhibitor NL.3 (
The ability to modulate NEDD4L activity is of particular interest, because elevated cell surface expression of ENaC and NCC (Na+—Cl− Co-transporter, another NEDD4L substrate) in the distal nephron causes increased Na+ reabsorption and salt-induced hypertension (Ronzaud et al., 2013). Indeed, mutations in the PY motifs of ENaC, which prevent proper NEDD4L binding to and suppression of this channel, cause Liddle syndrome, a hereditary hypertension (Lifton et al., 2001). Likewise, renal tubular deficiency of NEDD4L causes salt-induced hypertension by elevated NCC and ENaC abundance and function (Ronzaud et al., 2013). The increased NCC function and hypertension partially resembles Pseudohypoaldosteronism II (PHA II), another genetic hypertension caused by elevated NCC function due to mutations in its regulators, the WNK kinases (Wilson et al., 2001). Moreover, NEDD4L targets ENaC in lung epithelia, and NEDD4L depletion there causes massive inflammation and airway mucus plugging, resembling lung disease in cystic fibrosis patients (Kimura et al., 2011).
Thus, our identification of UbV activators of NEDD4L function could point to a novel therapeutic avenue for the treatment of hypertension and inflammation. This would require a proof that UbVs can function in mammalian tissues, not just in isolated cells. To this end, we utilized the recently developed technology to grow three-dimensional intestinal epithelial organoids (mini-guts) from intestinal stem cells (Sato and Clevers, 2013) and grew mouse distal colon organoids; the distal colon strongly expresses both ENaC and NEDD4L ((Duc et al., 1994) and Jiang & Rotin, unpublished). Consistent with inhibition of ENaC function observed in MDCK cells, lentiviral transduction of NL.1 caused organoid luminal swelling due to reduced fluid reabsorption into the media, while expression of NL.3 had the opposite effect (
To test whether UbVs can be used in a screen to discover unknown biological functions of HECT E3s in an unbiased and high throughput manner, we used our UbV panel to globally interrogate the family for roles in cell migration, a pathway known to involve ubiquitination and that is central to embryonic development and plays a major role in cancer invasion and metastasis (Deng and Huang, 2014; Simpson et al., 2008). While SMURF2 and HACE1 have been implicated in cell migration by RNA interference (Castillo-Lluva et al., 2013; David et al., 2014; Jin et al., 2009), we wondered whether our unprecedented ability to activate (or block) enzyme activity with UbVs could both score these positive controls and also potentially reveal roles for other HECT E3s not known previously as regulators of this pathway. To this end, we transduced HCT116 human colon cancer carcinoma cells with a pool of 83 distinct lentiviruses, each containing an inducible defined UbV expression cassette targeting one of 19 HECT E3s or one of 13 other proteins, and analyzed the migratory response in a trans-well migration assay by deep sequencing (
Upon induction of UbV expression by doxycycline and as expected based on RNA interference experiments (Castillo-Lluva et al., 2013; Jin et al., 2009), our screen identified inhibitors of HACE1 (HA.3) and SMURF2 (S2.5) that increased or decreased cell migration, respectively (
All DNA constructs used to produce proteins for UbV selections and subsequent assays were listed in Table 7. The following proteins were subjected to UbV selections: HECT domains of human ITCH, NEDD4, NEDD4L, SMURF1, SMURF2, WWP2, HECW1, HECW2, HERC1, HERC2, HERC4, HERC6, HACE1, HUWE1, UBE3A, UBE3C, EDD1, KIAA0317, HECTD1 (His- and Avi-tagged for in vivo biotinylation (Kay et al., 2009), pET28 vector, domain boundary shown in Table 7), full length human WWP1 and yeast Rsp5 (GST tagged). PCR amplified DNA fragments encoding the indicated UbVs with an N-terminal FLAG epitope tag were cloned into Gateway Entry vector pDONR221 (Thermo Scientific) according to the manufacturer's instructions and then transferred into Gateway Destination expression vector pET53 (His-tagged, Thermo Scientific). The above-mentioned plasmids were used to transform Escherichia coli BL21 (DE3) for protein expression. Protein expression was induced by addition of IPTG (isopropyl β-D-1-thiogalactopyranoside, Bioshop) at mid-log phase to a final concentration of 1 mM. After incubation overnight at 16° C. with shaking, cell pellets were collected by centrifugation (12,200×g, 10 min) and lysed, and proteins were purified using Ni-NTA Agarose (Qiagen 30250) at 4° C. following the manufacturer's instructions. The purity of eluted fractions was determined by polyacrylamide gel electrophoresis. Protein concentrations were determined by measuring the absorption at 280 nm (Nanodrop 1000, Thermo Scientific). Eluted proteins were dialyzed into 50 mM HEPES buffer pH 7.5, 250 mM NaCl, 5% glycerol, 1 mM DTT and stored at 4° C. or frozen at −80° C. for further applications.
Protein constructs used in biochemical assays, Octet bio-layer interferometry and crystallization are listed in Table 7. All constructs were made using standard molecular cloning methods or QuickChange mutagenesis. All proteins were expressed in BL21 (DE3) Codon Plus (RIL) Escherichia coli and purified using GST-affinity or nickel-affinity chromatography depending on the expression tags. Protein tags including GST, MBP, and SUMO2 were released by TEV or SENP2 protease. After proteolysis treatment, subsequent purifications including dialysis, ionic exchange and size exclusion chromatography were applied to obtain pure fractions of target proteins. Proteins were in final buffer containing 25 mM Tris pH 7.6, 200 mM NaCl and 3 mM DTT. Tag-free ubiquitin were purified by acidic precipitation followed by ionic exchange and size exclusion in 25 mM HEPES pH 7.0, 200 mM NaCl and 3 mM DTT. Pure proteins were concentrated, aliquoted, flash-frozen by liquid nitrogen and stored at −80° C.
To crosslink fluorescent probe on His-1CysUb, WBP2 or S-WBP2-1K, proteins were first treated with 10 mM DTT for 30 minutes, then desalted in 25 mM HEPES pH7.0 and 150 mM NaCl by Zeba spin columns or PD-10 columns. 10-fold molar excess maleimide-linked fluorescein (AnaSpec) dissolved in DMSO was mixed with His-1 CysUb or WBP2 at 4° C. for 1 hour. Unused fluorescein cross-linker was quenched by 50 mM DTT. Reductive lysine methylation on ubiquitin was carried out by mixing proteins with DMAB (dimethylamine borane complex) and formaldehyde at 4° C. overnight. Excess DMAB and formaldehyde were quenched by 50 mM Tris pH 8.0. Both fluorescein-labeled proteins and methylated proteins were purified by thorough desalting procedures and size exclusion to remove unused chemicals and precipitated proteins.
Ubiquitin Variant (UbV) SelectionThe phage displayed UbV library used in this study was re-amplified from Library 2 as described (Ernst et al., 2013). Protein immobilization and UbV binding selections were performed according to established protocols (Tonikian et al., 2007). Purified HECT E3 ligases were coated on 96-well MaxiSorp plates (Thermo Scientific 12565135) by adding 100 μL of 1 μM proteins and incubating overnight at 4° C. Five rounds of selections using the phage-displayed UbV library were performed against immobilized proteins. As seen in
Proteins in study were immobilized on 384-well MaxiSorp plates (Thermo Scientific 12665347) by adding 30 μL of 1 μM proteins for overnight incubation at 4° C. Phage and protein ELISA against immobilized proteins was performed as described (Ernst et al., 2013). Binding of phage was detected using anti-M13-HRP antibody (GE Healthcare 27942101) and binding of FLAG-tagged UbVs was detected using anti-FLAG-HRP antibody (Sigma-Aldrich A8592). To measure the half maximal binding concentration (EC50) of UbVs binding to HECT E3 ligases, the concentration of UbVs or wild type Ub was varied from 0 to 4 μM (24 points, 1:2 dilution), while the concentration of target proteins immobilized on the plate remained at 1 μM. EC50 values were calculated using the GraphPad Prism software with the built-in equation formula (non-linear regression curve).
Bio-Layer Interferometry (BLI)Concentrated analyte and ligand proteins were diluted into BLI reaction buffer (25 mM HEPES pH 7.0, 150 mM NaCl, 0.1 mg/ml bovine serum albumin, 0.01% Tween20). BLI experiments were performed on an Octet RED96 system (ForteBio) using anti-GST antibody biosensors for GST-tagged ligands (HECT domains) and His-tagged analytes or native WT ubiquitin at 25° C. 7-9 dilution points of analytes covering a wide concentration range were applied. Sensorgram raw data was processed and extracted by Octet Analysis 9.0 software. Dissociation constants (KD) were obtained by fitting the response wavelength shifts in the steady-state regions using single-site binding system (Eq. 1) or nonequivalent two-site binding system (Eq. 2) shown below.
where Req is value of steady-state response shift in each sensorgram curve, [C] is the titrant concentration, Rmax is the maximal response in the steady-state region, KD is the binding constant for single-site binding system and KD1 and KD2 are two binding constants of nonequivalent two-site binding system. In both equations, Rmax and KD values are unknown and Levenberg-Marquardt algorithm was used to perform iterative non-linear least squares curve fitting in Profit 6.2 (QuantumSoft) to obtain the fitted Rmax and KD.
Protein Crystallization and Data CollectionSix HECT E3-UbV complexes were crystallized: NEDD4LHECT-UbV NL.1, WWP1HECT-UbV P2.3-UBCH7, WWP1HECT-UbV P1.1, Rsp5HECT-UbV R5.4, ITCHHECT-UbV IT.2, and NEDD4HECT-UbV N4.4. Crystallization conditions and data analysis details are described below.
NEDD4LHECT-Ub V NL. 1NEDD4LHECT-NL.1 complex was prepared by 2-step GST and Ni-NTA affinity co-pulled down followed by TEV proteolysis, dialysis, ionic exchange and size exclusion. Proteins were concentrated to 22-26 mg/ml in 25 mM HEPES pH 7.0, 150 mM NaCl and 5 mM DTT. Crystals grew at 4° C. in 1:1 volumetric ratio of protein and reservoir buffer (0.1 M sodium cacodylate pH 6.0, 0.18 M NaCl, 5-6% polyethylene glycol (PEG) 8000, 0.7% 1-butanol) by the hanging-drop vapor diffusion method and were improved by streak seeding. Crystals were cryoprotected in reservoir solution supplemented with 35% glycerol.
WWP1HECT-Ub V P2.3-UBCH7GST-TEV-WWP1HECTΔ5 (C-terminal 5 residues removed), GST-TEV-P2.3 UbV and SUMO-GG-UBCH7-His6 were purified separately by affinity (GST for WWP1 and P2.3 or Ni-NTA for UBCH7), protease digestion (TEV for WWP1 and P2.3 or SENP2 protease for UBCH7), ionic exchange and size exclusion. WWP1HECT-P2.3-UBCH7 complex was created by directly mixing WWP1HECT Δ5, P2.3 and UBCH7 at 1:1.5:1.5 molar ratio, respectively and was concentrated to 8-10 mg/ml for crystallization. Crystals grew by hanging-drop vapor diffusion method at 23° C. and quality was improved by streak-seeding in 0.1 M sodium citrate pH 5.2, 10% isopropanol, 8% PEG 3350. Cryoprotectant supplemented with 8% xylitol, 8% glycerol and 8% ethylene glycol in reservoir solution was used.
WWP1HECT-UbV P1.1GST-TEV-P1.1 UbV was purified by GST-affinity, TEV protease digestion and size exclusion. 10 mg/ml complex of WWP1HECT-P1.1 was made by mixing 1:2 molar ratio of WWP1HECT Δ5 and P1.1, respectively. Crystals of WWP1HECT-P1.1 were grew at both 4° C. and 23° C. by hanging-drop vapor diffusion method and quality was improved by streak-seeding in 0.17 M ammonium sulfate, 25% glycerol and 25% PEG 3350 at 23° C. Reservoir solution was used as cryoprotectant for crystals.
Rsp5HECT-UbV R5.4Expressed GST-TEV-Rsp5HECT and His-R5.4 UbV are co-pulled down by GST and Ni-NTA affinity sequentially. GST tag was removed by TEV protease digestion. The complex was purified by sized exclusion (buffer: 25 mM HEPES, 150 mM NaCl and 2 mM DTT) and concentrated to 12.5 mg/ml. Crystal of Rsp5HECT-R5.4 complex grew at 23° C. in 1:1 volumetric ratio of protein and reservoir buffer (0.1 M Bis-Tris, pH 5.5, 0.2-0.25 M ammonium acetate, 14% PEG 3350) by the hanging-drop vapor diffusion method. Crystals were cryoprotected in reservoir solution supplemented with 8% xylitol, 8% glycerol and 8% ethylene glycol.
ITCHHECT-Ub V IT.2His-TEV-ITCHHECT and His-IT.2 were expressed in BL21 (DE3) strain and separately pulled down from cobalt-affinity column. TEV-cleaved ITCHHECT and His-IT.2 were further purified by ionic Q column. 1:2 molar ratio of ITCHHECT and IT.2 were mixed to reach 17 mg/ml for crystallization screening. Crystals were grown in 1.6 M ammonium sulfate, 0.2 M sodium acetate, 0.1 M HEPES pH 7.5, 5% ethylene glycol in hanging drop setup at 20° C. Solution containing well solution and 20% glycerol was used as cryoprotectant for crystals.
NEDD4HECT-Ub V N4.4NEDD4HECT and His-N4.4 were expressed and purified with the purification protocols for ITCHHECT-IT.2 complex. NEDD4HECT-N4.4 complex was prepared by mixing 2-fold His-N4.4 to NEDD4HECT. The final concentration is 15 mg/ml. The protein sample was mixed with Trypsin at a 1:1000 (W/W) Trypsin:protein ratio before setting up crystallization. Crystals were grown in 20% PEG 8000, 10% glycerol, 0.1 M HEPES pH 7.0 in hanging drop setup at 20° C. 20% glycerol with reservoir solution is used as cryoprotectant for crystals.
Diffraction data were processed with HKL2000 (Otwinowski and Minor, 1997) for NEDD4LHECT-NL.1, HKL3000 (Otwinowski and Minor, 1997) for ITCHHECT-IT.2, and NEDD4HECT-N4.4 and RAPD (rapd.nec.aps.anl.gov/rapd) for Rsp5HECT-R5.4, WWP1HECT-P2.3-UBCH7 and WWP1HECT-P1.1. All structures except of ITCHHECT-IT.2 were determined by molecular replacement using Phaser (McCoy et al., 2007) with NEDD4L (PDB: 2ONI), WWP1 (PDB: 1ND7), NEDD4 (PDB: 2XBB) or UBCH7 (PDB: 4Q5E) as search models. For ITCHHECT-IT.2, phasing was solved by molecular replacement using the CCP4 suite programs BALBES and MOLREP with previous ITCHHECT structure (PDB: 3TUG) as the search model. In the crystal structure, two UbV IT.2 were crystallized with one ITCHHECT. The UbV IT.2 bound to N-lobe exosite is proposed formed by crystal packing. Model constructions and rebuildings were performed in Coot (Emsley et al., 2010) and refined by Phenix (Adams et al., 2010) or REFMAC5 (Murshudov et al., 1997) in CCP4 suite (Winn et al., 2011). MolProbity (Chen et al., 2010) was used to evaluate qualities of all crystal structures. Molecular interactions in the HECT-UbV structures were analyzed by NACCESS (Hubbard, 1993), PDB ePISA (Krissinel and Henrick, 2007) and MacPyMOL (Schrödinger).
Biochemical Assays Pulse-Chase Ubiquitination AssaysThe biochemical assays were performed and monitored using either fluorescently labeled ubiquitin (Ub*, * stands for fluorescein probe) or substrates (WBP2* or S-WBP2-1K*). In all UbV-treated assays, 10-fold molar ratio of UbV/E3 was used to saturate HECT E3 with UbV during the entire reaction time. All reacted samples were quenched by mixing with SDS sample loading buffer, separated by SDS-PAGE and analyzed based on fluorescent signals of Ub*, WBP2* or S-WBP2-1K*. A Typhoon FLA9500 Phosphoimager (GE Healthcare) was used to scan fluorescent gel images.
Assays Detected by Fluorescence SignalsTo monitor Ub* transferred from E2 to E3 (E2-to-E3), di-ubiquitin chain synthesis (Ub˜Ub*) or substrate (WBP2, Sna3 and Sna4) ubiquitination, pulse-chase assay was applied with 2 steps. First, 20 μM E2 (UBCH5B or UBCH7) was mixed with 500 nM E1 in reaction solution (25 mM HEPES pH 7.5, 200 mM NaCl, 10 mM MgCl2, 2 mM ATP and 0.04 mg/ml bovine serum albumin) at room temperature for 30 minutes to generate charged E2 (E2˜Ub*). Then E1 activity was quenched by 25 mM HEPES pH 7.0, 100 mM NaCl and 50 mM EDTA. Second, E2-to-E3, Ub˜Ub* or substrate˜Ub reactions ran on ice were initiated by loading E2-Ub* to solution containing varied E3, E3, and free ubiquitin or substrate, respectively. 100 mM DTT in SDS sample loading buffer was used to check the formation of thioester bonded E3˜Ub* intermediate in pulse-chase reactions. Details of each biochemical assay shown in this study are described here. For E2-to-E3 pulse chase assays with inhibitor UbVs in
Rapid-quench flow kinetic studies were carried out at 25° C. using the KinTek RQF-3 instrument as described previously (Kamadurai et al., 2013). 2 μM of UBCH5B˜Ub was mixed with solution composed of 4 μM E3 (Rsp5FL or Rsp5WW(proximal)-HECT), 2 μM UbV R5.4 and 30 μM Biotin-Sna3.
Autoubiqutination of Rsp5FL was carried out by mixing 50 nM E1, 200 nM UBCH7, 200 nM Rsp5FL, 20 μM fluorescein-labeled ubiquitin and 2 μM UbVs (for control, buffer was loaded). The reactions ran room temperature for 15 minutes and were quenched by SDS sample buffer.
The encounter assays were carried out at room temperature by mixing two subset mixtures. The first subset has fluorescently labeled WBP2* or S-WBP2-1K*, E3 and free ubiquitin (or methylated ubiquitin) while the second subset contains E1 and charged UBCH7˜Ub mixed with buffer or 30-fold WBP2 (30-fold to WBP2* or S-WBP2-1K*) for the multiple turnover and competition reactions, respectively. Both subsets were prepared in 25 mM HEPES pH 7.5, 200 mM NaCl, 2 mM ATP, 10 mM MgCl2 and 0.04 mg/ml bovine serum albumin. The reactions were initiated by mixing the two subsets and quenched by SDS sample loading buffer at indicated reaction time points. To observe the chain elongation on S-WBP2-1K*, a prime reaction was performed to generate 30˜40% portion of monoubiquinted or diubiquitinated S-WBP2-1K*. The reaction was then mixed with 30-fold WBP2 or buffer for single or multiple encounter reactions. The prime reaction ran in the same described buffer with 400 nM E3, 3 μM UBCH7˜Ub, 80 nM E1 and 400 nM S-WBP2-1K*.
Competition AssayPurified NEDD4L, oxyester-linked UBCH5B˜Ub (Kamadurai et al., 2009) and UbV NL.3 were selected for the assays. 3 different mixed samples were prepared to evaluate competition. (A) 1:1 mixed NEDD4L and UBCH5B˜Ub, (B) 1:5 mixed NEDD4L and UbV NL.3 and (C) 1:1:5 mixed NEDD4L, UBCH5B˜Ub and UbV NL.3. In sample C NEDD4L and UBCH5B were mixed for 10 minutes on ice followed by addition of UbV NL.3. Samples were loaded in native gel (Bencsath et al., 2002).
Ubiquitination Assays with Immunoblotting
Biochemical reactions to study HECT E3 ligases autoubiquitination activity were performed in a volume of 25 μl in a buffer of 50 mM Tris pH 8.0, containing E1/UBE1 (50 nM, Boston Biochem E304), E2 as indicated (1 μM, kindly provided by Pankaj Garg), ubiquitin (20 μM, Boston Biochem U100H), HECT E3s as indicated (1 μM), and UbVs (10 μM). After incubation at room temperature for 60 min, reactions were stopped by the addition of 10 mM EDTA and SDS-PAGE sample buffer and resolved using 4-20% gradient gel (Bio-Rad 4561096). Mono- and poly-ubiquitinated HECT E3s were evaluated by western blotting. To assess the E3 activity of HACE1 on Rac1 GTPase in vivo, CHO cells (5×106) were transfected with 5 μg of HA-Rac1Q61 L, 5 μg His6-ubiquitin, 2 μg myc-HACE1 and 1 or 5 μg of FLAG-UbV expression plasmids described in this study. Measurement of Rac1 ubiquitination was performed as described previously (Doye et al., 2012). Briefly, 24 h after transfection CHO cells were lysed in 1 ml of BU buffer (20 mM Tris-HCl, pH 7.5, 200 mM NaCl, 10 mM imidazole, 0.1% (v/v) Triton X-100, 8 M urea). Samples were homogenized, centrifuged 10 min at 10,000 g at room temperature. An aliquot of 50 μl was collected (Total protein input). In parallel, 0.1 ml of cobalt beads (Talon, Clontech) 50% slurry in BU buffer were added to each 0.9 ml assay supernatants and incubated at room temperature 1 hour on a rotating shaker. Beads were washed three times in BU and resuspended in one volume Laemmli blue buffer 2× followed by western blotting. The RhoB ubiquitination assay was performed as described (Wang et al., 2014). For in vivo assay, the whole cell lysates were subjected to anti-HA immunoprecipitation and followed by anti-FLAG western blotting to detect ubiquitinated FLAG-RhoB. For in vitro assay, GST-RhoB were purified using glutathione sepharose beads and added into a volume of 25 μl in a buffer of 50 mM Tris pH 8.0, containing E1/UBE1 (50 nM), E2/UBE2L3 (1 μM), ubiquitin (20 M), HECT E3s as indicated (1 μM), and with and without NEDD4L UbV NL.1 (10 μM). MG-132 was used at 10 μM (Boston Biochem, I-130).
DNA Constructs for Mammalian Cell ExperimentsAll DNA constructs used in the mammalian cell culture experiments were listed in Table 7. UbV was transferred to mammalian expression vectors either by Gateway methods or PCR sub-cloning. The WWP2 construct was obtained from the Human ORFeome collection (version 5.1), and ubiquitin construct was a gift from R. Baer (Columbia University, New York. USA). The WWP2 and UbV constructs were sub-cloned into pDONR vector and then into Myc-tagged or FLAG-tagged destination vectors using Gateway Technology (Invitrogen). The constructs pLVE-NL.1 and pLVE-NL.3 were cloned as follows: BamH1 site with N-terminal V5 tag containing the start code and Spel site at the C-terminus with stop code were added to the UbV-WZ-12 (NL.1) and UbV-WZ-14 (NL.3) by PCR. After sequence verification, they were cloned into the lentiviral expression vector, pLVE (homemade by Rotin lab with IRES-EGFP, dual Zeocin resistance for bacterial and cell cultures). The expressions of the constructs were verified with western blot by transfecting the plasmids into 293T cells and blotted by V5 antibody. pXJ-HA-Rac1Q61 L, pKH3-HACE1 and pRBG4-His6-ubiquitin (pCW7) were reported before (Torrino et al., 2011). Hace1 cDNA from pKH3-HACE1 was subcloned BamHI-EcoRI in pRK5-myc-HACE1. The Lentiviral Destination (pLD) Vector pLD-puro-TnZsGreen was constructed by replacing the versatile affinity (VA) tag from the pLD-puro-TnVA (Mak et al., 2010) with the green fluorescent protein ZsGreen using Nhel/Agel restriction sites. For shRNA-mediated gene silencing, sequences of the control and shRNAs targeting Rac1 and RhoB are available upon request. The vector pDEST-5′3x-FLAG-pcDNA5-FRT/TO was a gift from Dr. Anne-Claude Gingras and pLenti CMV rtTA3 Blast (w756-1) was a gift from Dr. Eric Campeau (Addgene plasmid #26429). The FLAG-RhoB and GST-RhoB expression vector was kindly provided Dr. Hong-Rui Wang.
Cell Culture and TransfectionCells were cultured in DMEM (HEK293T and MDA-MB-231 cells) or McCoy's 5A (HCT116 cells) medium, supplemented with 10% fetal bovine serum (FBS), 100 U/ml of penicillin and 100 μg/ml of streptomycin. Chinese hamster ovary (CHO) epithelial cells were obtained from ATCC (CCL-61). Cells are grown in “DSG” medium, composed of DMEM/HAM-F12 (Life Technologies) supplemented with 10% (v/v) fetal bovine serum (EU Approved Origin, Invitrogen) and 50 μg/mL Gentamicin. The ENaC line, 409, established from MDCK (Madin Darby Canine Kidney) Cell, Type I, stably expressing 3 ENaC subunits, α, β and γ, was cultured in DMEM plus 10% FBS, 1× antibiotics and antimycotics, 600 μg/ml G418, 50 μg/ml hygromycin B and 2 μg/ml puromycin at various confluences for western blot, ELISA and Ussing chamber assays. All cell lines were maintained at 37° C. incubator with 5% CO2. Lipofectamine 2000 (Life technologies) was used for transient transfection according to the manufacturer's instructions. For tet/dox inducible UbV expression cell lines (e.g. NL.1 and HU.1), FLAG-UbVs were inserted into Flp-In T-REx HCT116 cells using the Flp-in T-REx system according to the manufacturer's instructions (Life Technologies). Cells were selected with hygromycin (20 μg/ml) for 2 weeks.
Lentivirus TransductionV5 N-terminally tagged UbVs (NL.1 and NL.3) were cloned in the lentiviral vector pLVE/Zeo and packaged into viruses. The viruses were transduced into MDCK cell line stably expressing tagged αβγENaC α3xHA; βmyc,T7; γFLAG-ENaC) (Lu et al., 2007) and selected with 100 μg/ml Zeocin (Life Technologies) to obtain individual clones. Survival clones were then expanded and tested for expression of V5-tagged UbVs. Clones with good expression of either NL.1 (clone 3) or NL.3 (clone 1) were used in subsequent assays. For UbV library-expressing cells, lentiviral ZsGreen-UbV clones were pooled at equimolar amounts and used for lentiviral packaging in HEK293T cells. HCT116 cells were transduced with the lentiviral pool at a low multiplicity of infection (M.O.I)<0.3. Transduced cells were selected with puromycin (1 μg/ml) for 7 days. For single UbV-expressing cell lines, lentiviral ZsGreen-UbV clones were individually used to infect HCT116 and MDA-MB-231 cells followed by puromycin selection (1 μg/ml) for 7 days.
Antibodies for Western Blotting and Immunoprecipitation (IP)Western blotting and IP assays were performed according to standard protocols, as previously described (Ernst et al., 2013). Anti-Ub monoclonal antibody (clone FK2, Millipore 04-263, 1:3000) was used for auto-ubiquitination assays. For NEDD4L cellular assays, the following antibodies were used: anti-α ENaC (1:500) (Santa Cruz, sc-21012), anti-HA (Clone 16B12, Biolegend, #901515, 1:10000); anti-FLAG (Clone OTI4C5, OriGene, TA50011-1, 1:10000); anti-Myc (Clone 4A6, EMD Millipore, 05-724, 1:2000); anti-V5 (AbD Serotec, MCA1360, 1:1000); and anti-β-actin (Sigma, A2228, 1:10,000). For WWP2 cellular assays, the following antibodies were used: anti-α-tubulin (Sigma-Aldrich, T6199, 1:5000), anti-HA (Sigma-Aldrich, H9658, 1:5000), and anti-FLAG (Sigma-Aldrich, F1804, 1:10000); anti-myc (Santa Cruz, sc-40, 1:5000); anti-PTEN (Santa Cruz, sc-7974, 1:1000). For HACE1 cellular assays, the following antibodies were used: anti-HA (Covance, clone 16B12, 901501, 1:5000); anti-Myc (Santa Cruz, sc-40, 1:5000); and anti-FLAG (Sigma-Aldrich, F1804, 1:5000). For HUWE1 cellular assays, the following antibodies were used: anti-HUWE1 (Bethyl, A300-486A, 1:2000); anti-cMyc (Cell Signaling, 5605, 1:1000); anti-FLAG (Sigma-Aldrich, F1804, 1:10000); anti-actin (Sigma, A2228, 1:10,000). For cell migration assays, the following antibodies were used: Rho-GTPase Ab Sampler Kit (Cell Signaling, 9968S); anti-actin (Bethyl, A300-485A, 1:5000); anti-RhoB (Santa Cruz, sc-180, 1:1000); anti-V5 (Invitrogen, 1:5000); anti-myc (Santa Cruz, sc-40, 1:5000); anti-HA (Santa Cruz, sc-7392, 1:5000).
Poly-Ub Capture from Cell Extracts
HEK293 Flp-In T-REx (HFT) cells were grown in DMEM with 10% fetal bovine serum, 15 μg/ml Blasticidin and 100 μg/ml Zeocin. To generate HFT cells conditionally expressing UbV NL.1, the gene was cloned into pcDNA5-FRT/TO-FLAG-FRT-Hygromycin based vector and the plasmid transfected into HFT cells followed by selection with Hygromycin (100 μg/ml). To induce low UbV NL.1 expression, cells were treated with 0.5 μg/ml doxycycline (DOX) for the time indicated. At the indicated times, cells were washed twice with ice cold PBS and lysed in lysis buffer (50 mM Tris/HCl pH 7.5, 1 mM EDTA, 1 mM EGTA, 50 mM NaF, 5 mM sodium pyrophosphate, 10 mM sodium 2-glycerol 1-phosphate, 1 mM sodium orthovanadate, 1% (v/v) NP-40, 1 μg/ml aprotinin and leupeptin, 1 mM benzamidine, 1 mM AEBSF, 10 μM PYR-619 and 100 mM chloroacatemide), to produce whole-cell extracts. Whole cell extract derived ubiquitylated proteins were purified using Halo-4×UBAUBQLN1 as described (Ordureau et al., 2014). Briefly, whole-cell extracts (0.5 mg) that were lysed in lysis buffer containing 100 mM chloroacetamide were incubated at 4° C. for 6 h with 40 μL of Halo-4×UBAUBQLN1 beads (pack volume). Following four washes with lysis buffer containing 0.5 M NaCl and four washes in 10 mM Tris (pH 8.0), proteins were released from Halo-4×UBAUBQLN1 beads using 6 M guanidine HCL. Samples were subjected to reduction (10 mM TCEP) and alkylation (20 mM chloroacetamide) followed by TCA precipitation. Samples were digested overnight at 37° C. with Lys-C and trypsin [in 100 mM tetraethylammonium bromide, 0.1% Rapigest (Waters Corporation), 10% (vol/vol) acetonitrile (ACN)]. Digests were acidified with an equal volume of 5% (vol/vol) formic acid (FA) to a pH of 2 for 30 min, dried down, resuspended in 5% (vol/vol) FA, and subjected to AQUA/PRM analysis as described below.
UB-AQUA/PRM ProteomicsUB-AQUA/PRM was performed largely as described previously but with several modifications (Ordureau et al., 2015a; Phu et al., 2011). A collection of heavy-labeled reference peptides each containing a single 13C/15N-labeled amino acid was produced at Cell Signaling Technologies and quantified by amino acid analysis. The 16 UB-AQUA reference peptides used for quantitation were previously listed in (Ordureau et al., 2014). UB-AQUA peptides from working stocks (in 5% FA) were diluted into the digested sample (in 5% FA) to be analyzed to an optimal final concentration predetermined for individual peptides. Samples mixed to AQUA peptides were oxidized with 0.05% hydrogen peroxide for 30 min, subjected to C18 StageTip desalting, and re-suspended in 5% FA. Experiments were performed with three independent experimental samples and analyzed sequentially by mass spectrometry. Our MS data were collected using a Q Exactive mass spectrometer (Thermo Fisher Scientific) as described in (Ordureau et al., 2015a) and peptides were separated using a 60 min gradient of 3%-25% acetonitrile in 0.125% FA with a flow rate of ˜300 nl·min−1. Raw files were searched and precursor and fragment ions quantified using Skyline version 3.1 (MacLean et al., 2010). Data generated from Skyline was exported into a Microsoft Excel spread sheet and GraphPad Prism for further analysis as previously described (Ordureau et al., 2014). Total Ub amount was determined as the average of the total Ub calculated for each individual locus (Phu et al., 2011) with the loci common between Ub and UbV NL.1 excluded. Samples were normalized to total amount of Ub (1,000 fmol).
ENaC Stability and Functional AssaysTo evaluate ENaC cell surface stability, MDCK cells stably expressing αβγENaC (Lu et al., 2007) together with NL.1 or NL.3 were seeded on 6-well plates and treated (or not) with 44.4 μM cycloheximide (CHX) at the indicated times. Cells were biotin-labeled with 0.5 mg/ml EZ-Link Sulfo-NHS-LC-Biotin (15 min, 4° C.), washed with PBS to remove unbound biotin, and lysed. Stability of surface ENaC was determined by quantifying αENaC, as described in further below, together with procedures for Ussing chamber analysis and Immunofluorescent (IF) confocal microscopy.
Stability of surface ENaC was determined by quantifying αENaC as follows. Briefly, 20 μg cell lysate was transferred to a 96-well ELISA plate (previously coated with anti-HA antibody (1:1000) and blocked with 0.5% BSA), incubated (4° C., 2 hr), plates washed (×3) with PBST (Phosphate Buffer Saline plus Tween 20) Strepavidin-HRP (1:1000) added (30 min, 4° C.) and washed (×5) with PBST. TMB substrate (eBioscience) was used for color development. Plates were read at 450 nm. All experiments were performed in duplicate and repeated 4 times. Data points were normalized to the αβγENaC-MDCK control (not expressing Ubvs and not treated with CHX), which was set to 100%. To assess ENaC protein stability assays, ENaC-plus Ubvs—expressing MDCK cell were seeded on 6 well plates in duplicates. 100 μM of chloroquine was added to one of duplicate wells overnight. Cells were lysed, quantified by the Bradford assay and analyzed by western blotting.
Ussing Chamber AnalysisThe above ENaC-plus UbVs—expressing MDCK cell lines were grown on Millicell Cell Culture Inserts (Millpore) with 10 μM amiloride (added apically) for 6 days and induced with 1 μM dexamethasone and 2 mM sodium butyrate overnight to induced ENaC expression. After amiloride wash out, the closed circuit currents (Isc) were recorded in Ussing chambers (Physiological Instruments) and apical amiloride added at the end of the recording. The assays were repeated 3 times.
Immunofluorescent (IF) Confocal MicroscopyMDCK cells stably expressing αβγENaC and the NEDD4L UbVs were cultured on coverslips in 6-well plates. Wells were washed twice with ice-cold 1 ml PBS and incubated for 5 min with Alexa-Fluor-647-conjugated ConcanavalinA (1:1000) on ice to visualize the plasma membrane. The cells were fixed with cold 95% methanol for 20 min on ice before blocking with 1:100 NGS in 5% Skim Milk (1 hr). Slides were stained overnight at 4° C. with rabbit polyclonal anti-αENaC antibody (1:500, Santa Cruz, sc-21012) that recognizes the extracellular domain. After three PBS washes, cells were permeabilized with 0.1% Triton X-100 for 10 min and incubated with goat anti-rabbit Alexa 555 Fluor-conjugated secondary antibody and briefly stained with DAPI. Cover slips were mounted with Dako Cytomation. Images were acquired using a Quorum WAveFX-X1 spinning disc confocal system at 60× magnification with an Olympus S-Apo 60×/1.35 oil objective (Quorum Technologies Inc., Guelph, Canada).
Mouse colonic organoids from a C57BL/6 background were generated as described (Sato and Clevers, 2013). For viral infection, these organoids were isolated from the Matrigel matrix through pipetting, dissociated through incubation with Accutase, and then transduced with lentiviral particles containing either control or ubiquitin variant (NL.1 or NL.3) constructs for 8 hrs at 37° C. Transduced fragments were re-embedded in fresh Matrigel and allowed to recover with complete media. Positive transduction was confirmed by expression of a bi-cistronic GFP reporter. Supplementation of the growth media with zeocin (2001 μg/mL) provided selection. Images were generated on a Leica DMI6000B epifluorescent microscope. Surface area measurements were calculated in ImageJ. For the amiloride rescue experiments, NL.3-variant organoids were incubated with or without amiloride (10 M) for 30 min followed by analysis of surface area by microscopy. Wild-type GFP-transduced organoids were included as controls. Histogram bars represent mean±SEM. N=30-40 organoids per condition.
RT-PCRmRNA levels of the α, β, and γsubunits of ENaC are similar in both distal colonic organoids and tissue. mRNA was isolated from both distal colonic and ileal intestinal organoids and from distal colonic epithelial cell scrapings using TRIZol elution and spin-column purification. mRNA expression was evaluated by real-time PCR and normalized to GAPDH. Relative levels were calculated using ENaC subunit expression in distal colonic epithelial tissue as the baseline. Histogram bars represent mean±SEM.
5×104 HCT116 cells expressing the UbV library or individual UbVs along with control cells were added on the upper chamber of cell-permeable inserts (Falcon #353182) placed into 12-well plates. Cells were maintained in FBS-free medium and treated with doxycycline (500 ng/mL) or vehicle and allowed to migrate for 48 h. 10% FBS-containing medium was used as the chemoattractant agent in the lower chamber. All experiments were performed in triplicate. For UbV library-expressing cells, migratory and non-migratory cells were harvested from the outer or inner membranes, respectively. Genomic DNA was extracted using the QIAmp Blood Maxi kit according to manufacturer's instructions (Qiagen) and prepared for Illumina sequencing as described in Supplemental Information. For single UbV-expressing cell lines, cells were stained using the Hemacolor stain kit according to the manufacturer's instructions (Harleco). Cells on the inner surface were swabbed out to remove non-migratory cells. Pictures of 5 different fields on the outer membrane were taken using a digital inverted microscope (EVOSfl-AMG) and migratory cells were counted.
Wound Healing AssayUbV-expressing cell lines were seeded at 1×104 cells/well in a 96-well Essen ImageLock plate (Essen Bioscience). After 16 hours cells were treated with doxycycline (500 ng/mL) or vehicle and allowed to grow to confluence. A 96-pin WoundMaker (Essen Bioscience) was used to simultaneously create precise and reproducible wounds in all wells of the 96-well plate by gently removing the cells from the confluent monolayer. After washing, the plate was placed inside the IncuCyte (Essen Bioscience) incubator. The IncuCyte software was set to scan the plate every hour for 36 hours using the “Scratch Wound” option as the “Experiment Type.” The data were analyzed by the “Relative Wound Density” program.
Illumina Sequencing and Data AnalysisGenomic DNA from migrated and non-migrated cells was precipitated using ethanol and sodium chloride, and resuspended in Buffer EB (10 mM Tris-HCl, pH 7.5). UbV sequences were amplified via PCR using primers harboring Illumina TruSeq adapters with i5 and i7 barcodes (primer sequences available upon request). PCR products were gel purified according to the manufacturer's instructions (Invitrogen).
Purified PCR products were combined in equimolar amounts, and sequenced on an Illumina MiSeq sequencer. To analyze the sequencing data, paired-end reads (2×262 bp) were processed using a bespoke Python pipeline as follows. First, reads were demultiplexed, allowing a single mismatch in each of the 8-base forward and reverse barcodes. Next, the UbV-encoding sequence was extracted from the reads using the barcode, Gateway AttB1, and FLAG sequences as landmarks to guard against frameshift mutations in the reads. Forward and reverse UbV sequences were aligned using the BioPython pairwise2.align.localms algorithm (options: match=1, mismatch=−10, gap_open_penalty=−20, gap_extend_penalty=−20, one_alignment_only), and sequences with an alignment score of at least 30 were retained. Unaligned reads or reads with gapped alignments were retained in a separate file for later inspection. Stand-alone BLAST (v. 2.2.18) was then used to match each spliced sequence to a FASTA file of UbV sequences (BLAST options: -p blastn -e 1e-100-a 6-m 7). The resulting XML file was parsed with a BioPython parser, and UbV sequences were counted and assembled into a matrix of m UbV sequences x n conditions.
REFERENCES
- Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010). PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66, 213-221.
- Alfano, D., Ragno, P., Stoppelli, M. P., and Ridley, A. J. (2012). RhoB regulates uPAR signalling. Journal of cell science 125, 2369-2380.
- Bencsath, K. P., Podgorski, M. S., Pagala, V. R., Slaughter, C. A., and Schulman, B. A. (2002). Identification of a multifunctional binding site on Ubc9p required for Smt3p conjugation. The Journal of biological chemistry 277, 47938-47945.
- Cao, Y., Wang, C., Zhang, X., Xing, G., Lu, K., Gu, Y., He, F., and Zhang, L. (2014). Selective small molecule compounds increase BMP-2 responsiveness by inhibiting Smurf1-mediated Smad1/5 degradation. Scientific reports 4, 4965.
- Castillo-Lluva, S., Tan, C. T., Daugaard, M., Sorensen, P. H., and Malliri, A. (2013). The tumour suppressor HACE1 controls cell migration by regulating Rac1 degradation. Oncogene 32, 1735-1742.
- Chen, V. B., Arendall, W. B., 3rd, Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., and Richardson, D. C. (2010). MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66, 12-21.
- Cohen, P., and Tcherpakov, M. (2010). Will the ubiquitin system furnish as many drug targets as protein kinases? Cell 143, 686-693.
- David, D., Jagadeeshan, S., Hariharan, R., Nair, A. S., and Pillai, R. M. (2014). Smurf2 E3 ubiquitin ligase modulates proliferation and invasiveness of breast cancer cells in a CNKSR2 dependent manner. Cell division 9, 2.
- Deng, S., and Huang, C. (2014). E3 ubiquitin ligases in regulating stress fiber, lamellipodium, and focal adhesion dynamics. Cell adhesion & migration 8, 49-54.
- Doye, A., Mettouchi, A., and Lemichez, E. (2012). Assessing ubiquitylation of Rho GTPases in mammalian cells. Methods Mol Biol 827, 77-86.
- Duc, C., Farman, N., Canessa, C. M., Bonvalet, J. P., and Rossier, B. C. (1994). Cell-specific expression of epithelial sodium channel alpha, beta, and gamma subunits in aldosterone-responsive epithelia from the rat: localization by in situ hybridization and immunocytochemistry. The Journal of cell biology 127, 1907-1921.
- Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010). Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66, 486-501.
- Ernst, A., Avvakumov, G., Tong, J., Fan, Y., Zhao, Y., Alberts, P., Persaud, A., Walker, J. R., Neculai, A. M., Neculai, D., et al. (2013). A strategy for modulation of enzymes in the ubiquitin system. Science 339, 590-595.
- Escobedo, A., Gomes, T., Aragon, E., Martin-Malpartida, P., Ruiz, L., and Macias, M. J. (2014). Structural basis of the activation and degradation mechanisms of the E3 ubiquitin ligase Nedd4L. Structure 22, 1446-1457.
- French, M. E., Kretzmann, B. R., and Hicke, L. (2009). Regulation of the RSP5 ubiquitin ligase by an intrinsic ubiquitin-binding site. The Journal of biological chemistry 284, 12071-12079.
- Gallagher, E., Gao, M., Liu, Y. C., and Karin, M. (2006). Activation of the E3 ubiquitin ligase Itch through a phosphorylation-induced conformational change. Proceedings of the National Academy of Sciences of the United States of America 103, 1717-1722.
- Herrador, A., Leon, S., Haguenauer-Tsapis, R., and Vincent, O. (2013). A mechanism for protein monoubiquitination dependent on a trans-acting ubiquitin-binding domain. The Journal of biological chemistry 288, 16206-16211.
- Huang, L., Kinnucan, E., Wang, G., Beaudenon, S., Howley, P. M., Huibregtse, J. M., and Pavletich, N. P. (1999). Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade. Science 286, 1321-1326.
- Hubbard, S. J. T., J. M. (1993). ‘NACCESS’, Computer Program, Department of Biochemistry and Molecular Biology, University College London.
- Huibregtse, J. M., Scheffner, M., Beaudenon, S., and Howley, P. M. (1995). A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proceedings of the National Academy of Sciences of the United States of America 92, 2563-2567.
- Inoue, S., Hao, Z., Elia, A. J., Cescon, D., Zhou, L., Silvester, J., Snow, B., Harris, I. S., Sasaki, M., Li, W. Y., et al. (2013). Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15. Genes & development 27, 1101-1114.
- Jin, C., Yang, Y. A., Anver, M. R., Morris, N., Wang, X., and Zhang, Y. E. (2009). Smad ubiquitination regulatory factor 2 promotes metastasis of breast cancer cells by enhancing migration and invasiveness. Cancer research 69, 735-740.
Kamadurai, H. B., Qiu, Y., Deng, A., Harrison, J. S., Macdonald, C., Actis, M., Rodrigues, P., Miller, D. J., Souphron, J., Lewis, S. M., et al. (2013). Mechanism of ubiquitin ligation and lysine prioritization by a HECT E3. eLife 2, e00828.
- Kamadurai, H. B., Souphron, J., Scott, D. C., Duda, D. M., Miller, D. J., Stringer, D., Piper, R. C., and Schulman, B. A. (2009). Insights into ubiquitin transfer cascades from a structure of a UbcH5B approximately ubiquitin-HECT(NEDD4L) complex. Molecular cell 36, 1095-1102.
- Kamynina, E., Tauxe, C., and Staub, O. (2001). Distinct characteristics of two human Nedd4 proteins with respect to epithelial Na(+) channel regulation. American journal of physiology. Renal physiology 281, F469-477.
- Kathman, S. G., Span, I., Smith, A. T., Xu, Z., Zhan, J., Rosenzweig, A. C., and Statsyuk, A. V. (2015). A Small Molecule That Switches a Ubiquitin Ligase From a Processive to a Distributive Enzymatic Mechanism. J Am Chem Soc.
- Kay, B. K., Thai, S., and Volgina, V. V. (2009). High-throughput biotinylation of proteins. Methods Mol Biol 498, 185-196.
- Kim, H. C., and Huibregtse, J. M. (2009). Polyubiquitination by HECT E3s and the determinants of chain type specificity. Molecular and cellular biology 29, 3307-3318.
- Kim, H. C., Steffen, A. M., Oldham, M. L., Chen, J., and Huibregtse, J. M. (2011). Structure and function of a HECT domain ubiquitin-binding site. EMBO reports 12, 334-341.
- Kimura, T., Kawabe, H., Jiang, C., Zhang, W., Xiang, Y. Y., Lu, C., Salter, M. W., Brose, N., Lu, W. Y., and Rotin, D. (2011). Deletion of the ubiquitin ligase Nedd4L in lung epithelia causes cystic fibrosis-like disease. Proceedings of the National Academy of Sciences of the United States of America 108, 3216-3221.
- Kirkpatrick, D. S., Gerber, S. A., and Gygi, S. P. (2005). The absolute quantification strategy: a general procedure for the quantification of proteins and post-translational modifications. Methods 35, 265-273.
- Krissinel, E., and Henrick, K. (2007). Inference of macromolecular assemblies from crystalline state. Journal of molecular biology 372, 774-797.
- Lifton, R. P., Gharavi, A. G., and Geller, D. S. (2001). Molecular mechanisms of human hypertension. Cell 104, 545-556.
- Lin, D. Y., Diao, J., and Chen, J. (2012). Crystal structures of two bacterial HECT-like E3 ligases in complex with a human E2 reveal atomic details of pathogen-host interactions. Proceedings of the National Academy of Sciences of the United States of America 109, 1925-1930.
- Lu, C., Pribanic, S., Debonneville, A., Jiang, C., and Rotin, D. (2007). The PY motif of ENaC, mutated in Liddle syndrome, regulates channel internalization, sorting and mobilization from subapical pool. Traffic 8, 1246-1264.
- MacLean, B., Tomazela, D. M., Shulman, N., Chambers, M., Finney, G. L., Frewen, B., Kern, R., Tabb, D. L., Liebler, D. C., and MacCoss, M. J. (2010). Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26, 966-968.
- Maddika, S., Kavela, S., Rani, N., Palicharla, V. R., Pokorny, J. L., Sarkaria, J. N., and Chen, J. (2011). WWP2 is an E3 ubiquitin ligase for PTEN. Nature cell biology 13, 728-733.
- Mak, A. B., Ni, Z., Hewel, J. A., Chen, G. I., Zhong, G., Karamboulas, K., Blakely, K., Smiley, S., Marcon, E., Roudeva, D., et al. (2010). A lentiviral functional proteomics approach identifies chromatin remodeling complexes important for the induction of pluripotency. Molecular & cellular proteomics: MCP 9, 811-823.
- Mari, S., Ruetalo, N., Maspero, E., Stoffregen, M. C., Pasqualato, S., Polo, S., and Wiesner, S. (2014). Structural and functional framework for the autoinhibition of Nedd4-family ubiquitin ligases. Structure 22, 1639-1649.
- Maspero, E., Mari, S., Valentini, E., Musacchio, A., Fish, A., Pasqualato, S., and Polo, S. (2011). Structure of the HECT:ubiquitin complex and its role in ubiquitin chain elongation. EMBO reports 12, 342-349.
- Maspero, E., Valentini, E., Mari, S., Cecatiello, V., Soffientini, P., Pasqualato, S., and Polo, S. (2013). Structure of a ubiquitin-loaded HECT ligase reveals the molecular basis for catalytic priming. Nature structural & molecular biology 20, 696-701.
- McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. J. (2007). Phaser crystallographic software. J Appl Crystallogr 40, 658-674.
- Mund, T., Lewis, M. J., Maslen, S., and Pelham, H. R. (2014). Peptide and small molecule inhibitors of HECT-type ubiquitin ligases. Proceedings of the National Academy of Sciences of the United States of America 111, 16736-16741.
- Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997). Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53, 240-255.
- Nalepa, G., Rolfe, M., and Harper, J. W. (2006). Drug discovery in the ubiquitin-proteasome system. Nature reviews. Drug discovery 5, 596-613.
- Ogunjimi, A. A., Wiesner, S., Briant, D. J., Varelas, X., Sicheri, F., Forman-Kay, J., and Wrana, J. L. (2010). The ubiquitin binding region of the Smurf HECT domain facilitates polyubiquitylation and binding of ubiquitylated substrates. The Journal of biological chemistry 285, 6308-6315.
- Ordureau, A., Heo, J. M., Duda, D. M., Paulo, J. A., Olszewski, J. L., Yanishevski, D., Rinehart, J., Schulman, B. A., and Harper, J. W. (2015a). Defining roles of PARKIN and ubiquitin phosphorylation by PINK1 in mitochondrial quality control using a ubiquitin replacement strategy. Proceedings of the National Academy of Sciences of the United States of America 112, 6637-6642.
- Ordureau, A., Munch, C., and Harper, J. W. (2015b). Quantifying ubiquitin signaling. Molecular cell 58, 660-676.
- Ordureau, A., Sarraf, S. A., Duda, D. M., Heo, J. M., Jedrychowski, M. P., Sviderskiy, V. O., Olszewski, J. L., Koerber, J. T., Xie, T., Beausoleil, S. A., et al. (2014). Quantitative proteomics reveal a feedforward mechanism for mitochondrial PARKIN translocation and ubiquitin chain synthesis. Molecular cell 56, 360-375.
- Otwinowski, Z., and Minor, W. (1997). Processing of X-ray diffraction data collected in oscillation mode. Method Enzymol 276, 307-326.
- Persaud, A., Alberts, P., Mari, S., Tong, J., Murchie, R., Maspero, E., Safi, F., Moran, M. F., Polo, S., and Rotin, D. (2014). Tyrosine phosphorylation of NEDD4 activates its ubiquitin ligase activity. Science signaling 7, ra95.
- Petroski, M. D. (2008). The ubiquitin system, disease, and drug discovery. BMC biochemistry 9 Suppl 1, S7.
- Phillips, A. H., Zhang, Y., Cunningham, C. N., Zhou, L., Forrest, W. F., Liu, P. S., Steffek, M., Lee, J., Tam, C., Helgason, E., et al. (2013). Conformational dynamics control ubiquitin-deubiquitinase interactions and influence in vivo signaling. Proceedings of the National Academy of Sciences of the United States of America 110, 11379-11384.
- Phu, L., Izrael-Tomasevic, A., Matsumoto, M. L., Bustos, D., Dynek, J. N., Fedorova, A. V., Bakalarski, C. E., Arnott, D., Deshayes, K., Dixit, V. M., et al. (2011). Improved quantitative mass spectrometry methods for characterizing complex ubiquitin signals. Molecular & cellular proteomics: MCP 10, M110 003756.
- Riling, C., Kamadurai, H., Kumar, S., O'Leary, C. E., Wu, K. P., Manion, E. E., Ying, M., Schulman, B. A., and Oliver, P. M. (2015). Itch WW domains inhibit its E3 ubiquitin ligase activity by blocking E2-E3 transthiolation. The Journal of biological chemistry.
- Rohde, J. R., Breitkreutz, A., Chenal, A., Sansonetti, P. J., and Parsot, C. (2007). Type III secretion effectors of the IpaH family are E3 ubiquitin ligases. Cell Host Microbe 1, 77-83.
- Ronchi, V. P., Klein, J. M., and Haas, A. L. (2013). E6AP/UBE3A ubiquitin ligase harbors two E2˜ubiquitin binding sites. The Journal of biological chemistry 288, 10349-10360.
- Ronzaud, C., Loffing-Cueni, D., Hausel, P., Debonneville, A., Malsure, S. R., Fowler-Jaeger, N., Boase, N. A., Perrier, R., Maillard, M., Yang, B., et al. (2013). Renal tubular NEDD4-2 deficiency causes NCC-mediated salt-dependent hypertension. J Clin Invest 123, 657-665.
- Rossi, M., Rotblat, B., Ansell, K., Amelio, I., Caraglia, M., Misso, G., Bernassola, F., Cavasotto, C. N., Knight, R. A., Ciechanover, A., et al. (2014). High throughput screening for inhibitors of the HECT ubiquitin E3 ligase ITCH identifies antidepressant drugs as regulators of autophagy. Cell death & disease 5, e1203.
- Rotin, D., and Kumar, S. (2009). Physiological functions of the HECT family of ubiquitin ligases. Nature reviews. Molecular cell biology 10, 398-409.
- Sato, T., and Clevers, H. (2013). Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science 340, 1190-1194.
- Scheffner, M., and Kumar, S. (2014). Mammalian HECT ubiquitin-protein ligases: biological and pathophysiological aspects. Biochimica et biophysica acta 1843, 61-74.
- Sheng, Y., Hong, J. H., Doherty, R., Srikumar, T., Shloush, J., Avvakumov, G. V., Walker, J. R., Xue, S., Neculai, D., Wan, J. W., et al. (2012). A human ubiquitin conjugating enzyme (E2)-HECT E3 ligase structure-function screen. Molecular & cellular proteomics: MCP 11, 329-341.
- Simpson, K. J., Selfors, L. M., Bui, J., Reynolds, A., Leake, D., Khvorova, A., and Brugge, J. S. (2008). Identification of genes that regulate epithelial cell migration using an siRNA screening approach. Nature cell biology 10, 1027-1038.
- Tonikian, R., Zhang, Y., Boone, C., and Sidhu, S. S. (2007). Identifying specificity profiles for peptide recognition modules from phage-displayed peptide libraries. Nature protocols 2, 1368-1386.
- Torrino, S., Visvikis, O., Doye, A., Boyer, L., Stefani, C., Munro, P., Bertoglio, J., Gacon, G., Mettouchi, A., and Lemichez, E. (2011). The E3 ubiquitin-ligase HACE1 catalyzes the ubiquitylation of active Rac1. Developmental cell 21, 959-965.
- Verdecia, M. A., Joazeiro, C. A., Wells, N. J., Ferrer, J. L., Bowman, M. E., Hunter, T., and Noel, J. P. (2003). Conformational flexibility underlies ubiquitin ligation mediated by the WWP1 HECT domain E3 ligase. Molecular cell 11, 249-259.
- Wang, H. R., Zhang, Y., Ozdamar, B., Ogunjimi, A. A., Alexandrova, E., Thomsen, G. H., and Wrana, J. L. (2003). Regulation of cell polarity and protrusion formation by targeting RhoA for degradation. Science 302, 1775-1779.
- Wang, M., Guo, L., Wu, Q., Zeng, T., Lin, Q., Qiao, Y., Wang, Q., Liu, M., Zhang, X., Ren, L., et al. (2014). ATR/Chk1/Smurf1 pathway determines cell fate after DNA damage by controlling RhoB abundance. Nature communications 5, 4901.
- Wiesner, S., Ogunjimi, A. A., Wang, H. R., Rotin, D., Sicheri, F., Wrana, J. L., and Forman-Kay, J. D. (2007). Autoinhibition of the HECT-type ubiquitin ligase Smurf2 through its C2 domain. Cell 130, 651-662.
- Wilson, F. H., Disse-Nicodeme, S., Choate, K. A., Ishikawa, K., Nelson-Williams, C., Desitter, I., Gunel, M., Milford, D. V., Lipkin, G. W., Achard, J. M., et al. (2001). Human hypertension caused by mutations in WNK kinases. Science 293, 1107-1112.
- Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G., McCoy, A., et al. (2011). Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67, 235-242.
- Zhang, W., and Sidhu, S. S. (2014). Development of inhibitors in the ubiquitination cascade. FEBS letters 588, 356-367.
- Zhang, Y., Zhou, L., Rouge, L., Phillips, A. H., Lam, C., Liu, P., Sandoval, W., Helgason, E., Murray, J. M., Wertz, I. E., et al. (2013). Conformational stabilization of ubiquitin yields potent and selective inhibitors of USP7. Nature chemical biology 9, 51-58.
Claims
1. A ubiquitin variant (Ubv) polypeptide comprising one or more substitution in one or more region of a ubiquitin polypeptide, wherein the region is selected from the group consisting of: wherein X2 is selected from the group consisting of A, D, E, H, K, L, P, Q, R, S, T, and Y; X4 is selected from the group consisting of A, C, F, I, L, R, S, V, and Y; X6 is selected from the group consisting of E, G, H, I, K, N, Q, R, S, V, W, and Y; X8 is selected from the group consisting of F, G, H, I, L, M, P, R, V, and Y; X9 is selected from the group consisting of A, F, G, I, K, L, M, N, P, R, S, and T; X10 is selected from the group consisting of A, D, G, L, R, V, and W; X11 is selected from the group consisting of D, E, H, I, K, L, M, N, P, Q, R, T, V, W, and Y; X12 is selected from the group consisting of D, G, I, L, N, P, S, T, V, and Y; X14 is selected from the group consisting of A, C, F, I, K, N, P, R, S, and T; and any X not specified optionally has the amino acid sequence of the corresponding position in SEQ ID NO:1; wherein X42 is selected from the group consisting of F, G, I, K, L, Q, R, S, T, and V; X44 is selected from the group consisting of F, I, L, T, and V; X46 is selected from the group consisting of A, G, H, L, R, S, T, and V; X47 is selected from the group consisting of A, D, G, R, S, and W; X48 is selected from the group consisting of K, M, N, Q, R, and T; X49 is selected from the group consisting of D, E, H, I, K, N, P, Q, R, and S; and any X not specified optionally has the amino acid sequence of the corresponding position in SEQ ID NO:1; and wherein X62 is selected from the group consisting of C, H, K, L, P, Q, R, and Y; X63 is selected from the group consisting of D, E, G, H, K, M, N, Q, R, and Y; X64 is selected from the group consisting of A, D, E, F, G, K, Q, R, T, V, W, and Y; X66 is selected from the group consisting of A, F, H, I, L, N, P, Q, R, S, T, and W; X68 is selected from the group consisting of G, F, H, L, N, R, S, T, W, and Y; X70 is selected from the group consisting of A, I, F, K, L, M, R, V, and W; X71 is selected from the group consisting of F, G, K, L, M, R, V, and Y; X72 is selected from the group consisting of G, I, K, P, Q, R, S, and T; X73 is selected from the group consisting of F, I, L, P, R, and T; X74 is selected from the group consisting of L, H, I, P, R, and V; X75 is selected from the group consisting of A, D, G, I, P, R, V, W, and Y; X76 is selected from the group consisting of A, D, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, and Y; X77 is selected from the group consisting of A, D, E, F, H, I, K, M, N, P, Q, R, S, T, V, and Y, or is absent; X78 is selected from the group consisting of A, D, E, F, H, I, K, L, N, P, Q, R, S, T, V, W, and Y, or is absent; and any X not specified optionally has the amino acid sequence of the corresponding position in SEQ ID NO:1; wherein any X specified in said Ubv polypeptide optionally has the amino acid sequence of the corresponding position in SEQ ID NO:1; or a fragment thereof, wherein the sequence of said Ubv polypeptide does not consist of SEQ ID NO:1.
- (a) region 1 (amino acids 2-14 of SEQ ID NO:1) wherein the polypeptide comprises the structure:
- X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14
- (b) region 2 (amino acids 42-49 of SEQ ID NO:1) wherein the polypeptide comprises the structure:
- X42-X43-X44-X-45-X46-X47-X48-X49
- (c) region 3 (amino acids 62-78 of SEQ ID NO:1) wherein the polypeptide comprises the structure:
- X62-X63-X64-X65-X66-X67-X68-X69-X70-X71-X72-X73-X74-X75-X76-X77-X78
2. The Ubv polypeptide of claim 1, wherein said Ubv polypeptide binds to NEDD4 (N4).
3. The Ubv polypeptide of claim 2, wherein the sequence of said Ubv polypeptide comprises a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:2-4 or a fragment thereof.
4. The Ubv polypeptide of claim 3, wherein the sequence of said Ubv polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs:2-4.
5. The Ubv polypeptide of claim 1, wherein said Ubv polypeptide binds to NEDD4L (NL).
6. The Ubv polypeptide of claim 5, wherein the sequence of said Ubv polypeptide comprises a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:5-8.
7. The Ubv polypeptide of claim 6, wherein the sequence of said Ubv polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs:5-8.
8. The Ubv polypeptide of claim 1, wherein said Ubv polypeptide binds to ITCH (IT).
9. The Ubv polypeptide of claim 8, wherein the sequence of said Ubv polypeptide comprises a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:9-12.
10. The Ubv polypeptide of claim 9, wherein the sequence of said Ubv polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs:9-12.
11. The Ubv polypeptide of claim 1, wherein said Ubv polypeptide binds to SMURF1 (S1).
12. The Ubv polypeptide of claim 11, wherein the sequence of said Ubv polypeptide comprises a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:13-17.
13. The Ubv polypeptide of claim 12, wherein the sequence of said Ubv polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs:13-17.
14. The Ubv polypeptide of claim 1, wherein said Ubv polypeptide binds to SMURF2 (S2).
15. The Ubv polypeptide of claim 14, wherein the sequence of said Ubv polypeptide comprises a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:18-22.
16. The Ubv polypeptide of claim 15, wherein the sequence of said Ubv polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs:18-22.
17. The Ubv polypeptide of claim 1, wherein said Ubv polypeptide binds to WWP1 (P1).
18. The Ubv polypeptide of claim 17, wherein the sequence of said Ubv polypeptide comprises a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:23-26.
19. The Ubv polypeptide of claim 18, wherein the sequence of said Ubv polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs:23-26.
20. The Ubv polypeptide of claim 1, wherein said Ubv polypeptide binds to WWP2 (P2).
21. The Ubv polypeptide of claim 20, wherein the sequence of said Ubv polypeptide comprises a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:27-30.
22. The Ubv polypeptide of claim 21, wherein the sequence of said Ubv polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs:27-30.
23. The Ubv polypeptide of claim 1, wherein said Ubv polypeptide binds to HECW1 (W1).
24. The Ubv polypeptide of claim 23, wherein the sequence of said Ubv polypeptide comprises a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:31-34.
25. The Ubv polypeptide of claim 24, wherein the sequence of said Ubv polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs:31-34.
26. The Ubv polypeptide of claim 1, wherein said Ubv polypeptide binds to HECW2 (W2).
27. The Ubv polypeptide of claim 26, wherein the sequence of said Ubv polypeptide comprises a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:35-38.
28. The Ubv polypeptide of claim 27, wherein the sequence of said Ubv polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs:35-38.
29. The Ubv polypeptide of claim 1, wherein said Ubv polypeptide binds to RSP5 (R5).
30. The Ubv polypeptide of claim 29, wherein the sequence of said Ubv polypeptide comprises a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:39-44.
31. The Ubv polypeptide of claim 30, wherein the sequence of said Ubv polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs:39-44.
32. The Ubv polypeptide of claim 1, wherein said Ubv polypeptide binds to HERC1 (H1).
33. The Ubv polypeptide of claim 32, wherein the sequence of said Ubv polypeptide comprises a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:45 and 46.
34. The Ubv polypeptide of claim 33, wherein the sequence of said Ubv polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs:45 and 46.
35. The Ubv polypeptide of claim 1, wherein said Ubv polypeptide binds to HERC2 (H2).
36. The Ubv polypeptide of claim 35, wherein the sequence of said Ubv polypeptide comprises a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:47 and 48.
37. The Ubv polypeptide of claim 36, wherein the sequence of said Ubv polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs:47 and 48.
38. The Ubv polypeptide of claim 1, wherein said Ubv polypeptide binds to HERC4 (H4).
39. The Ubv polypeptide of claim 38, wherein the sequence of said Ubv polypeptide comprises a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:49-52.
40. The Ubv polypeptide of claim 39, wherein the sequence of said Ubv polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs:49-52.
41. The Ubv polypeptide of claim 1, wherein said Ubv polypeptide binds to HERC6 (H6).
42. The Ubv polypeptide of claim 41, wherein the sequence of said Ubv polypeptide comprises a sequence that is at least 90% identical to SEQ ID NO:53.
43. The Ubv polypeptide of claim 42, wherein the sequence of said Ubv polypeptide comprises SEQ ID NO:53.
44. The Ubv polypeptide of claim 1, wherein said Ubv polypeptide binds to HACE1 (HA).
45. The Ubv polypeptide of claim 44, wherein the sequence of said Ubv polypeptide comprises a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:54-56.
46. The Ubv polypeptide of claim 45, wherein the sequence of said Ubv polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs:54-56.
47. The Ubv polypeptide of claim 1, wherein said Ubv polypeptide binds to HUWE1 (HU).
48. The Ubv polypeptide of claim 47, wherein the sequence of said Ubv polypeptide comprises a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:57 and 58.
49. The Ubv polypeptide of claim 48, wherein the sequence of said Ubv polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs:57 and 58.
50. The Ubv polypeptide of claim 1, wherein said Ubv polypeptide binds to UBE3C (3C).
51. The Ubv polypeptide of claim 50, wherein the sequence of said Ubv polypeptide comprises a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:59 and 60.
52. The Ubv polypeptide of claim 51, wherein the sequence of said Ubv polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs:59 and 60.
53. The Ubv polypeptide of claim 1, wherein said Ubv polypeptide binds to HECTD1 (D1).
54. The Ubv polypeptide of claim 53, wherein the sequence of said Ubv polypeptide comprises a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:61-64.
55. The Ubv polypeptide of claim 54, wherein the sequence of said Ubv polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs:61-64.
56. The Ubv polypeptide of claim 1, wherein said Ubv polypeptide binds to EDD1 (ED).
57. The Ubv polypeptide of claim 56, wherein the sequence of said Ubv polypeptide comprises a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:65 and 66.
58. The Ubv polypeptide of claim 57, wherein the sequence of said Ubv polypeptide comprises a sequence selected from the group consisting of SEQ ID NOs:65 and 66.
59. The Ubv polypeptide of claim 1, wherein said Ubv polypeptide binds to KIAA0317 (KI).
60. The Ubv polypeptide of claim 59, wherein the sequence of said Ubv polypeptide comprises a sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs:67-70.
61. The Ubv polypeptide of claim 60, wherein the sequence of said Ubv polypeptide is selected from the group consisting of SEQ ID NOs:67-70.
62. The Ubv polypeptide of any one of claims 3, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 19, 21, 22, 24, 25, 27, 28, 30, 31, 33, 34, 36, 37, 39, 40, 42, 43, 45, 46, 48, 49, 51, 52, 54, 55, 57, 58, 60, or 61, wherein said Ubv polypeptide comprises a fragment of a polypeptide comprising the indicated sequence identifier or a sequence at least 90% identical thereto.
63. A nucleic acid molecule encoding a Ubv polypeptide of any one of claims 1-62.
64. A recombinant expression vector comprising the nucleic acid molecule of claim 63.
65. A host cell comprising the nucleic acid molecule of claim 63 or the recombinant expression vector of claim 64.
66. A method of obtaining a Ubv polypeptide that modulates an activity or property of a HECT E3 ligase, the method comprising:
- (a) randomizing ubiquitin residues to produce a combinatorial library of Ubv polypeptides, and
- (b) selecting Ubv polypeptides that specifically bind to one or more HECT E3 ligase.
67. The method of claim 66, wherein the randomized residues (a) contact the N-lobe exosite of a HECT E3 ligase, (b) contact the E2 site of a HECT E3 ligase, and/or (c) are within region 1 (amino acids 2-14), region 2 (amino acids 42-49), and/or region 3 (amino acids 62-78) of ubiquitin.
68. The method of claim 66 or 67, wherein said HECT E3 ligase is selected from the group consisting of NEDD4 (N4), NEDD4L (NL), ITCH (IT), SMURF1 (S1), SMURF2 (S2), WWP1 (P1), WWP2 (P2), HECW1 (W1), HECW2 (W2), RSP5 (R5), HERC1 (H1), HERC2 (H2), HERC3 (H3), HERC4 (H4), HERC5 (H5), HERC6 (H6), HACE1 (HA), HUWE1 (HU), UBE3A (3A), UBE3B (3B), UBE3C (3C), HECTD1 (D1), EDD1 (ED), KIAA0317 (KI), HECTD1, HECTD2, HECTD3, HECTD4, G2E3, and TRIP12.
69. The method of any one of claims 66-68, further comprising assessing a selected Ubv for its effects on an activity of a HECT E3 ligase or on a cellular function or activity modulated by a HECT E3 ligase.
70. A method of modulating an activity or property of a HECT E3 ligase, the method comprising contacting said HECT E3 ligase with an agent that binds to the N-lobe exosite of said HECT E3 ligase or to the E2 site of said HECT E3 ligase.
71. The method of claim 70, wherein said agent increases the activity of said HECT E3 ligase.
72. The method of claim 70, wherein said agent decreases the activity of said HECT E3 ligase.
73. The method of any one of claims 70-72, wherein said agent comprises a Ubv polypeptide, a nucleic acid molecule encoding a Ubv polypeptide, or a fragment thereof.
74. The method of claim 73, wherein said Ubv polypeptide is a Ubv polypeptide of any one of claims 1 to 62 or a fragment thereof, or said nucleic acid molecule is a nucleic acid molecule of claim 63 or a fragment thereof.
75. The method of any one of claims 70-74, wherein said agent has specificity for a particular HECT E3 ligase.
76. The method of any one of claims 70-74, wherein said agent is active against more than one HECT E3 ligase.
77. The method of any one of claims 70-76, wherein said HECT E3 ligase is in a cell.
78. The method of claim 77, wherein said cell is comprised within a subject.
79. The method of claim 78, wherein said subject has a disease or condition selected from the group consisting of hypertension, inflammation, and cancer.
80. A method of treating hypertension, inflammation, or cancer in a subject, the method comprising modulating the activity of a HECT E3 ligase in a cell of the subject according to the method of any one of claims 70-79.
81. A method of identifying an agent that modulates the activity of a HECT E3 ligase, the method comprising contacting a complex comprising a HECT E3 ligase and a Ubv polypeptide that binds to said HECT E3 ligase with a candidate agent, and determining whether said agent affects the binding of said Ubv to said HECT E3 ligase or an activity of said complex.
82. The method of claim 81, wherein said candidate agent comprises a small molecule compound.
83. The method of claim 81 or 82, wherein said HECT E3 ligase is selected from the group consisting of NEDD4 (N4), NEDD4L (NL), ITCH (IT), SMURF1 (S1), SMURF2 (S2), WWP1 (P1), WWP2 (P2), HECW1 (W1), HECW2 (W2), RSP5 (R5), HERC1 (H1), HERC2 (H2), HERC3 (H3), HERC4 (H4), HERC5 (H5), HERC6 (H6), HACE1 (HA), HUWE1 (HU), UBE3A (3A), UBE3B (3B), UBE3C (3C), HECTD1 (D1), EDD1 (ED), KIAA0317 (KI), HECTD1, HECTD2, HECTD3, HECTD4, G2E3, and TRIP12.
84. The method of any one of claims 81-83, wherein said Ubv polypeptide is selected from a Ubv polypeptide of any one of claims 1-62 or a fragment thereof.
Type: Application
Filed: Apr 13, 2020
Publication Date: Sep 3, 2020
Inventors: Wei ZHANG (Missisauga), Sachdev SIDHU (Toronto)
Application Number: 16/846,688
